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Abstract 
The varied nature of biological profiles of the quinolone scaffold has attracted 
researcher's interests in exploring novel quinolone-based compounds. Novel quinolone 
derivatives are designed to overcome unwanted effects such as bacterial resistance, 
tox icities and side effects of existing molecules. Based on understanding of mechanism of 
action of quinolones, while their s ide effects, profile, bacterial resistance and efficacy 
may be altered. 
Among the newly synthesized biologically active polycyclic qu inolones, the sulfur-
conta ining polycyc lic quinolone nucle i such as thiazolo-, th iazeto- and thieno-
derivatives are of biological interest. While there are numerous research reports available 
on various polycyclic quinolones, for instance 4 -oxo-thiazo lo [3,2-a] quino line-3-
carboxylic ac id derivatives, 4-oxo-thieno[3,2-a]quino line-3-carboxylic ac id derivatives 
etc., there are very few studies reported for the 4-oxo-thiazeto [3,2-a] quino lines. The 
work presented in this thesis was performed in order to discover novel 4 -oxo-thiazeto [3, 
2-a] quinolone derivatives with potential antibacteria l activ ity, focussing on activity 
against resistant bacterial strains. This work traverses from design and synthesis of a 
series of 4-oxo-thiazeto [3, 2-a] quinoline derivatives to their in vitro evaluation for 
microbiological activ ity, and fina lly ends with docking studies. Unfortunate ly, the 
antibacteria l activity of the synthesized compounds was insignificant. Thus, in order to 
comprehend the mechanism behind the insignificant antibacterial activ ity, docking studies 
were performed on the DNA gyrase enzyme for a certain compounds. 
The results obtained fro m docking stud ies showed that the synthesized 4-oxo-th iazeto [3 , 
2-a] quinolone derivatives could interact w ith the DNA gyrase enzyme, form ing 
ii 
reversible binding interaction with the vanous domains of this enzyme, while other 
reported active antibacterial compounds from this class bind irreversibly with the A TP 
binding site. 
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Chapter 1 
Introduction 
1.1 Antibiotics 
1.1.1 Introduction 
Antibiotics are simply the chemical compounds which can inhibit the growth of and/or 
kill bacteria and other micro-organisms [I]. Antibiotics may be of natural origin obtained 
directly from micro-organisms. This definition covers traditional antibiotic agents such as 
aminoglycosides, tetracyclines, macrolides and ~-lactams. The up-to-date definition of the 
antibiotic has been modified with the inclusion of chemically modified antibiotics and those of 
fully synthetic chemical origins, such as quinolones [4(1H)-oxoquinoline-3-carboxylic acid 
derivatives] , sulfonamides, and oxazolidinones, etc. [2]. Antibiotics may act by inhibition of 
various biological processes in bacterial cells, such as inhibition of protein biosynthesis and 
RNA/DNA replication/repair in bacterial cell wall synthesis. Ideal antibiotics are compounds 
which can selectively affect bacteria with minimum or no effect on the host cells. This 
characteristic of antibiotics contributes to reduction of undesired effects on host body cell.. 
However, among the above-mentioned mechanisms, inhibition of bacterial cell wall synthesis 
and folate coenzyme synthesis are unique to bacterial cells, whereas, the two processes of 
inhibition of protein biosynthesis and RNA/DNA replication/repair synthesis are not unique to 
bacterial cells and are also present in mammalian cells as well [3]. 
The story of naturally occurring antibiotics originated in 1928, when Alexander Fleming 
discovered penicillin while working on Staphylococcus bacteria. When culturing a sample of 
Staphylococcus aureus, he observed the growth of a mold (via contamination) in some areas of 
the agar plate. Interesting ly, no bacteria were found to grow in the region surrounding the mold. 
This suggested that the mold, which was later identified as Penicillium notatum, inhibited the 
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growth of Staphylococcus aureus [4]. Later on, the first antibiotic penicillin was isolated from 
cultures of the above mold. Penicillin was first used clinically during World War II and became 
widely available to the civilian market shortly after the war through the increase in bulk 
manufacturing capability [5]. Over the next couple of decades, thriving antibiotic research 
produced numerous natural product derived classes of antibiotics including tetracyclines [6], 
glycopeptides [7], macrolides, and phenylpropanoids [8]. Daptomycin, a lipopeptide 
representative of the naturally derived antibiotic class, was introduced into the market in 2003 
[9]. 
The first sulfonamide as well as the first synthetic commercially available antibacterial 
agent was Prontosil, which was marketed by Bayer in 1935 [I 0]. It took almost 30 years 
before the next fully synthetic antibacterial class of compounds, the quinolones (Nalidixic 
acid), hit the market. It was discovered by Lesher et al. in 1962 as an impurity while 
manufacturing chloroquine, an antimalarial agent at that time. Nalidixic acid was found to be 
effective in the treatment of urinary tract infections [II]. Nearly four more decades passed 
before the next synthetic antibiotic class, the oxazolidinones, would enter clinical use in 2000 
[ 12]. Figure 1.1 illustrates the classification of antibiotics. 
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Antibiotics 
1 1 l 
Bacterial Spectrum Route of Administration Type of Activity 
~ ~ 
Broad Nru.TOW Injectable Oral Bactericidal Bacteriostatic 
Figure 1.1. Common plan of classifications for antibiotics [ 13] 
The long periods of relative idleness in research on antibiotics can be attributed to 
numerous causes such as the belief that bacterial infections would shortly be no longer a threat 
in most countries, along with changes in research priorities at major pharmaceutical companies. 
Blossoming genomics research and ignorance for discovery of new chemical entities/ drugs, as 
well as a major shift in the source of new drug molecules from natural products to small 
synthetic molecules were also other reasons for the idleness in natural product antibiotic 
research. 
1.1.2 Mechanism of action of Antibiotics and Resistance 
While antibiotics may act by targeting various biological processes in bacterial cells (Figure 1.2 
[14] and Table 1.1 ), inhibition of bacterial cell wall formation is known to be the most common 
mechanism of action of antibacterial agents [ 13, 14]. 
Antibacterial agents can also inhibit protein synthesis (translation). Some other mechanisms 
4 
include: alteration of cell membranes, inhibition of nucleic acid synthesis and antimetabolite 
activity. Bacteria can become resistant to a drug by a specific internal mechanism. There are few 
proposed mechanisms for the development of bacterial resistance including enzymes which can 
deactivate a drug via a chemical modification. Another path is the structural modification 
through which bacteria can modify target structures which render the drugs ineffective. Bacteria 
can also stimulate efflux proteins which can pump the drug out of the cell. Albeit, researchers 
were cognizant of bacterial resistance in the early 1960s [ 15, 16], and even with the vigilant and 
responsible use of clinical antibiotics, resistance has become increasingly challenging [ 17, 18]. 
In this context, even third line antibiotics, such as vancomycine, have become ineffective 
against resistant pathogens [ 19, 20). The contemporary increase in the risk of community-
acquired- and healthcare-acquired-methicillin resistant Staphylococcus aureus (MRSA) has 
brought the threat of antibiotic resistant into the public perception [ 19, 20). 
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Figure 1.2. Antibiotic targets and mechanisms of resistance (Figure adopted from web source: 
http :1/www .gustrength .com/health: anti biotic-resistance-questions-and-answers) [ 14] 
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Table 1.1. Examples and mechanism of action of antibiotic class by origin 
Origin Class Mechanism Example 
Natural Penicil lins Inhibition of cell wall biosynthesis Penicillin G 
Product 
Tetracyclines Doxycycline 
Protein synthesis inhibition by 
inhibiting 30S ribosomal subunit 
G I ycopeptides Vancomycin 
Inhibition of cell wall biosynthesis 
Macrolides Erythromycin 
Protein synthesis inhibition by 
blocking 50S rRNA complex 
Phenylpropanoids Chloramphenicol 
Protein synthesis inhibition 
Lipopeptides Cell membrane Daptomycin 
disruption/depolarization 
Synthetic Sulfonamides Prontosil 
Folate synthesis inhibition (by direct 
inhibition of dihydropterate 
Fluoroquinolones Inhibition of DNA replication Ciprofloxacin 
Oxazolidinones Linezolid 
Protein synthesis inhibition. 
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1.1.3 Natural vs. Synthetic antibiotics 
Natural antibiotics are metabolites produced by living organisms (obtained directly from the 
source, which is typically a plant, animal or a microorganism), whereas synthetic antibiotics are 
the product of laboratory-based chemical synthesis which may be prepared by complicated or 
simple processes. 
Moreover, these antibiotics differ from each other in terms of the onset and the duration of 
action. As observed to date, with few exceptions, synthetic antibiotics work faster and longer 
than the natural antibiotics. This phenomenon gives a good rational for the use of synthetic 
antibiotics in medical emergencies [21]. 
Additionally, safety profile is another characteristic in which these substances differ from each 
other. Even though synthetic antibiotics are very target specific compared to natural antibiotics, 
natural antibiotics are considered safer. Noteworthy, this comparison is not on the transient 
effect of a particular agent but is all about adverse effect upon long term basis. As we know, 
most of the synthetic antibiotics cause potentially dangerous adverse effects on long term use. 
However, with reference to the above discussion, natural antibiotics should be the preferred 
agents for the treatment of bacterial infections . On the contrary, most bacteria or 
microorganisms are capable of developing resistance to natural antibiotics if used for a long 
period of time. Emerging bacterial resistance generates the need of relatively novel antibacteria l 
agents and natural antibiotics are not sufficient to satisfy this need. 
In consideration of the severity of widespread bacterial resistance in addition to multidrug 
resistance, there is an incessant need for novel natural or synthetic antimicrobial agents [2 1 ]. 
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1.2 Quinolones: An Overview 
Quinolones are of prominent therapeutic importance because of a privileged basic ring skeleton. 
The concept of " privileged basic ring skeleton" was first proposed by Evans [22]. Privileged 
structure refers to a molecular scaffold whose structure contains two or three ring systems that 
are arranged in such a manner so as to allow a very high degree of versatility in binding with the 
receptors. In this perspective, a quinolone scaffold can be considered as a privileged basic ring 
skeleton [23]. 
Since the discovery of nalidixic acid by Lesher et a!. in 1962, more than I 0,000 quinolone 
derivatives have been patented or published [24]. Among these are clinically important 
antibacterial agents such as norfloxacin, ciprofloxacin, temafloxacin, ditloxacin and ofloxacin 
which possess the !-substituted 4-oxo-1 , 4-dihydroquinoline-3-carboxylic acid moiety. Based on 
their main clinical use and decade of discovery, they can be categorized into four different 
groups (A, B, C, and D) as depicted in Figure 1.3. 
Quinolones have an important place in the field of antibacterial drugs. Their therapeutic values 
as antibacterial agents have been known for over 50 years. They are still a hot topic for 
concurrent research because of continuous development of bacterial resistance against currently 
used antibiotics. This has directed the current trend of antibiotic research to focus mainly on the 
design and development of novel quinolone antibacterials that are active against resistant strains 
of bacteria [24, 25]. 
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• Nalidixic acid 
• Cinoxacin 
• Norfloxacin 
• Ofloxacin 
• Ciprofloxacin 
Group I 
Gram-
negative 
Systemics 
• Temafloxacin 
• Troafloxacin 
• Gatifloxacin 
• Clinafloxacin • Moxifloxacin 
• GarenoxaciA 
Figure 1.3. Chronological development of quinolones (suggested by the author of this thesis) 
1.2.1 Classification of Quinolones: 
Orig inally, the antibacteria l quino lone framework was derived from the naphthyridone-based 
compound, na lidix ic ac id (Table 1.2). Quino lones can be class ified into fo ur generations based 
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on antimicrobial activity, structural modifications and chronological order of discovery [26, 27]. 
The only characterization that is universally accepted is that the non-fluorinated quinolone 
derivatives are class ified as the first generation and the fluorinated counterparts are grouped into 
the later generations. Conversely, some lately discovered broad spectrum antibacterial 
quinolones, such as garenoxacin, do not have fluorine in their structure, despite being derived 
from the later generations of the tluoroquinolone class [26]. 
First generation: This generation of quinolones has been used for the treatment of uncomplicated 
urinary tract infections s ince their advent to the market. Nalidixic ac id, fi rst reported in 1962, 
was biologically active and is the parent compound of this generation [26, 27]. The fi rst 
generation agents display activity against Gram-negative bacteria, with the except ion of 
Pseudomonas species. They are used less often today because of their side effects and emergence 
of bacterial resistance. Interestingly, few first generation quinolones are still in use even after 
their genotoxic and carcinogenic effects [25]. 
Second generation: This generation of quinolones differs structurally from the first generation by 
containing a fluorine atom at the C-6 position. This generation of quinolones is also called 
"fluoroquinolones" (Table 1.2). Activities of the second generation agents are circumscribed to 
Gram-negative pathogens and recently included Pseudomonas species, but they a lso display 
activity against some Gram-positive species, such as Staphylococcus aureus [26] . Diseases that 
have been treated using second generation tluoroquinolones include urinary tract infect ions (both 
complicated and uncomplicated), pyelonephritis, sexually transmitted diseases, prostatit is, 
localized skin and soft ti ssue infections [27]. The second generation quinolones are further 
separated into subclasses lla and lib. Subclass lib compounds tend to have broad-spectrum uses, 
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particularly improved activity against Gram-positive bacteria and respiratory infections, and their 
long duration of action permit once daily dosing [27]. Perhaps the greatest well publicized use of 
a second generation fluoroquinolone, c iprotloxacin (Cipro), was when several government 
workers took it for prophylaxis during an anthrax scare in the fall of 200 I [26]. 
Third generation: Fluoroquinolones have applications against respiratory infections [27]. They 
exhibit broader-spectrum activity as compared to the first and second generation agents in the 
treatment of expanded Gram-positive and a few penicillin resistant bacteria. Third generation 
quinolones are also divided further in two subgroups of lila and lllb. The latter group is now 
considered as the fourth generation [27] . 
The difference between third and fourth generation fluoroquinolones is not well defined. Some 
agents such as moxitloxacin can be considered as either third or fourth generation, depending on 
the source by which they are obta ined . Usually, fourth generation tluoroquinolones have actions 
against similar infections as third generation drugs; additionally they demonastrate activ ity 
against anaerobic microbes as well as infections of the pelvis, abdomen, and nosocomial 
pneumoma. As compared to the first generation, activ ity profile of the second and third 
generation quino lones is not only retained, but is increased. Another characteristic of this class is 
that the fourth generation tluoroquinolones have activ ity against ciprotloxacin-resistant 
Pneumonococci [27]. 
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First 
Generation 
Second 
Generation 
Third 
Generation 
Fourth 
Generation 
Table 1.2. Some examples of each of quinolone generation 
Nalidixic acid 
0 )CC)COOH I .o I rN N HN-J L 
Ciprofloxacin 
CH3 0 WCOO< 
H3C~N ././ N 
HN~ ~ 
Grepatloxacin 
0 W OOO< 
H,C~N .0 N 
HN-J ~ 
H3C/ 
0 
Gatifloxacin 
C inoxacin 
0 
F~COOH 
~.) rN N 
HN_J l CH3 
Norfloxacin 
0 XXJCOOH 
HJCY"N 8 N 
~-J ¢r' l .o 
F m 
Temafloxacin 
0 CQW'oo" N _&. N L 
0 H H,c/ 
Moxitloxacin 
13 
Pimemidic Acid 
Otloxacin 
0 we= 
r N -;:'/ N , N~ O~CH H~ 3 
Levofloxacin 
0 
~cc:c~H r N ~ N S 0~Y"N~ "( 
Prulitloxacin 
1.2.2 Chemistry of Quinolones 
Replacement of a single carbon atom on a benzene ring with nitrogen results in pyridine 
skeleton, while the same replacement on a naphthalene nucleus (with fused pair of benzene 
rings) results in a quinoline or isoquinoline nuclei depending on the position of the carbon atom 
being replaced by nitrogen (Figure 1.4). Quinoline is a liquid at room temperature w ith a high 
boiling point, first extracted in 1834 from coal tar. lsoquinoline is a solid substance with a low 
melting point, first extracted in 1885 from the same source [28]. 
0 0 N co h N co N 
Benzene Pyridine Naphthalene Quinoline Is oquinoline 
Figure 1.4. Structures of pyridine and quinoline nuclei. 
The Schematic numbering of a quinoline nucleus is shown in Figure 1.5. 
Figure 1.5. Schematic numbering of quinoline nucleus. 
When a hydroxyl group is added to the C-2 or C-4 positions of a quinoline ring the 
corresponding tautomeric forms of hydroxquinolines and quinolones are formed as depicted in 
Figures 1.6 and 1.7. 
CO==ca~ ~ N OH _ij N 0 
H 
Figure 1.6. Tautomeric forms of 2-hydroxyquinoline and 2( I 1:1)--quinolone 
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c60H~~ ~.) N N 
H 
Figure 1.7. Tautomeric forms of 4-hydroxyquinoline and 4 (I H)-quinolone 
Various synthetic methods have been reported so far for the preparation of quinolones, 
few of which are described in the following section. 
1.2.2.1 Gould-Jacob's Quinolone Synthesis 
Unti l the end of the 1970s, the Gould Jacob' s quinolone synthesis was the most 
commonly used procedure for synthesizing I ,4-dihydro-4-oxo-quinoline-3-carboxylic 
acid derivatives. This method of preparation uses an addition-elimination reaction of 
vario us substituted anilines and dialkyl a lkoxymethylenemalonate as shown in Scheme 
1.1 [28]. The product of this reaction undergoes thermal cyclization when heated and 
produces quinoline-4( I H)-one system. N-Aikylation of this product, fol lowed by 
hydrolysis of the ester group, affords N-substituted-4-( I H)-quinolone-3-carboxylic acid. 
COOEt 
+ ('coo Et 
OEt 
EtOOC COOEt 
00dn•on-chmm.:tt1on ~ Qj 
NH 
~COOEt 
N) _ lnJn•l• " roO COOH I N 
I I 
R R 
Scheme 1.1. Gould-Jacobs reaction. 
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1.2.2.2 Dieckmann Cyclization of Diesters 
Pesson eta/. reported a simple and convenient, 5-step procedure fo r the synthesis of aza-
and diazaquinolone carboxylic acids [29]. This process involves an intramolecular 
cyclization of diesters in the presence of a base as depicted in Scheme 1.2. 
The first step is a regioselective reaction between ethyl ester of 2,6-dichloro-5-
fluoronicotonic acid (1) with N-acetylpiperazine which leads to the formation of 6-
piperaz inyl derivative 2. Further reaction of Compound 2 w ith the ethyl ester of 3-
ethylaminopropionic ac id affords Compound 3, which is a diester. Compound 3 wou ld 
further undergo intramolecular ring fo rmation w ith potassium tert-butoxide to yie ld ethyl 
ester of tetrahydroquinoline carboxylic acid 4. The dehydrogenation of Compound 4 by 
means of chloranil gives rise to the ethyl ester of naphthyridone carboxylic acid 5 which 
yie lds the corresponding fluoroquinolone (enoxacin) after hydrolys is. 
c 
[a) N-acetylpiperazine, CH,CN: b) Et H(CH, ),C02Et, DMF. NaHCO). 120 "C: c) KOC(CH,h, toluene: d) chloranil; e) OH-] 
Scheme 1.2. Synthesis of enoxacin by Dieckmann cyclization method 
16 
1.2.2.3 Conrad-Limpach 4-quinolone synthesis 
This reaction is a modification of Knorr quinoline synthesis in which condensation of~-
keto-esters and arylamines occurs at II 0 °C, then the resulting anil ides further cyclizes 
when reacted with concentrated sulphuric acid to yie ld 4-hydroxyquinolines. Mechanism 
of this reaction is a nucleophilic attack by aniline at the carbonyl group of the ester, 
followed by cyclization of the intermediate anilide. 
Modified reactions employed for the synthesis of 4-quinolones involves the reaction 
between aniline and 3-oxobutanoate at a temperature below 100 °C. The second step in 
this reaction involves cyclization in an inert solvent at a temperature around 250 °C to 
yield 4-quinolone derivative as shown in Scheme 1.3 [30]. 
< 100 °C 
NH2 
Scheme 1.3. Conrad-Limpach 4-quinolone synthesis 
1.2.2.4 Camps quinoline synthesis 
In this reaction the intramolecular cyclization and condensation occur under basic 
conditions. Fundamentally, it is the alkaline cyclization of an N-acylated-o-
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aminoacetophenone which affords the corresponding 2- or 4-hydroxyquinolines as shown 
in Scheme 1.4 [31-37]. 
~CH, __ o_H __ _. 
~0 
R 
Scheme 1.4. Camps quinoline synthesis 
1.2.2.5 Synthesis of quinolones by cycloaracylation reaction 
This cycloaracylation procedure has been developed by Grohe eta/. [38] in 1987. It starts 
with the formation of acylated product 8 via the reaction between 
2,4-dichloro-5-fluorobenzoyl chloride (6) and ethyl 3-cyclopropylaminoacrylate (7) tn 
the presence of triethylamine. Cyclization of 8 under the catalytic influence of potassium 
carbonate yields the ethyl ester of quinolone carboxylic acid 9, which is subsequently 
hydrolysed to its carboxylic acid derivative 10. The reaction of compound 10 with 
piperazine leads to the generation of a quinolone with antimicrobial properties (in this 
case, ciprofloxacin). Detailed procedure is depicted in Scheme 1.5 [37]. 
0 0 
F:nCOCI 
E<OO) 
a FroCOOE< FroCOOE< 
I~ + .. b .. I I HN Cl ° Cl NH Cl o- N 
Cl ° Cl ~ L L 8 6 9 
7 
18 
0 
.. .. 
FroCOOH I~ I rN ~ N 
HN~ L 
c 
cipronoxac in 
[a) NEt,, toluene; b) K1CO,, DMF; c) KOH; d) piperazine, DMSO] 
Scheme 1.5. Synthesis of ciprotloxacin by cycloaracylation reaction 
1.2.2.6 Meth-Cohn Quinolone Synthesis 
This approach of quino lone synthesis was developed by Meth-Cohn in 1986 [39] . In this 
reaction a Vilsmeier complex, which consist of N-methylformanilide (11) and phosphory l 
chloride, is reacted with methylmalo nyl chloride (12) to produce its quino linium salt 13. 
Thi s quino linium salt further reacts w ith ammonium hexatluorophosphate to afford 4-
ch loro-3-methoxycarbo nyl-1-methylquino linium hexatluorophosphate (14). Compound 
13 is also converted to methyl 1-methyl-4( lH)-qu ino lone-3-carboxylate (15) by treatment 
with excess a lka li fo llowed by ac idification as depicted in Scheme 1.6 . 
~ M e00CCH2COCI 
~N-CHO 12 
I 
Me 
11 
Scheme 1.6. Meth- Cohn quinolone synthes is 
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1.2.2.7 Biere and Seelen Approach for quinolone synthesis 
This method for quinolone synthesis has been developed in 1976 by Biere and 
Seelen as shown in Scheme 1.7 [40]. The reaction progresses with the Michael addition 
of methyl anthranilate (16) to dimethylacetylene dicarboxylate (17) to yield the enamino 
esters (18). This enamino ester undergoes further cyclization to the quinolone 
dicarboxylic ac id ester (19) in the presence of strong base such as sodium hydride or 
potassium tert-butoxide. The dicarboxylic acid (20) or the ester-carboxylic acid (21) are 
obtained after regioselective or complete alkal ine hydrolysis of 19. The quinolone 
carboxylic acid ester (22) is then obtained by thermal decarboxylation reaction at very 
high temperature from compound 21. 
CCCOOMe "' NH2 
16 
+ 
COO Me 
II 
COO Me 
17 
0 
ccJ:COOH 
~ N COOH 
H 
20 
+ 
COO Me 
~COOMe 
N 
H 
COO Me 
18 
0 
ccJ:COOMo 
I __., ~ 
~ COOH 
21 
0 
~COOMe 
~ .. ~ ~ N COOMe 
H 
19 
0 
roCOOMo 
I ~ 
N 
H 
22 
Scheme 1.7. Biere and Seelen approach for quinolone synthesis 
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1.2.3 Mechanism of action of fluoroquinolones as antibacterial agents 
The fluoroquinolone class of compounds exert their effect by inhibition of bacterial type II 
topoisomerases (DNA gyrase) or topoisomerase IV. Topoisomerase IV and DNA gyrase are the 
enzymes which pave the way for DNA replication by relaxing supercoiled DNA and once 
replication is done they induce supercoiling of DNA. Generally, topo IV and gyrase enzymes 
work to relax negatively supercoiled DNA by forming a break in one strand of double stranded 
DNA, passing the complementary strand through the break; then combining the separated ends 
again [41]. (Figure 1.8) 
A fluoroquinolone usually binds with the DNA topoisomerase units and form a ternary complex 
that inhibits DNA replication, thereby preventing bacterial cell division [ 42, 43]. Most 
fluoroquinolones predominantly bind with either topo IV or DNA gyrase. There are some 
fluoroquinolones that can bind with both enzymes and have nearly equal potency against Gram-
positive and Gram-negative bacteria, therefore being called as dual target agents [44]. The 
obvious fact is that the dual target agents are likely to be more active against resistant mutants. 
Quinolones are generally bactricidal in nature meaning that the ternary complexes formed by the 
first and second generation quinolones exclusively result in inhibition of bacterial growth [ 45, 
46]. 
By a unique mechanism which is novel but partially explained, few third and fourth generation 
fluoroquinolones are known to damage the ternary complex, resulting in fragmented DNA. This 
process is termed as a "rapid lethality" [47]. Additionally, there can be two diverse paths in the 
new rapid letha lity mechanism; first route requires protein synthesis while the second path does 
not depend on protein synthesis. The type of pathway is determined by particular the 
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fluoroquinolone in the ternary complex, but to date it is not known what properties of the 
fluoroquinolone lead to one mechanism over the other. 
GyrB 
GyrA 
Gyra e Trius 
GyrBJParE 
Target 
ParE 
Fluoroqulnolones 
Figure 1.8. Quinolone-enzyme Complex 
0 0 v 
(Figure adapted from web sources http://www.triusrx.com/trius-therapeutics-gyrbpare. 
php) [48] 
1.2.4 Bacterial Resistance 
Emerging bacterial res istance to most of the known antibiotics is a serious problem which needs 
immediate attention. To date, bacteria and fungi have been known to develop drug resistance by 
the fo llowing mechanisms: (a) producing enzymes that inactivate the drug or (b) modifying their 
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targets to render the drugs useless, or simply ' pump' the drugs out with the help of efflux 
proteins in order to lower their concentrations. [ 49] 
As stated, most common Gram-positive and Gram-negative bacteria have already developed 
resistance against various quinolone antibiotics. Bacteria usua lly opt for changing their target 
structures to acquire resistance to fluoroquinolones . They are reported to change or modify their 
target structure and/or conformation as a result of mutations leading to amino ac id changes. 
More specifically, they get the mutation in the area of the active site of GyrA (DNA gyrase) or 
ParC (Topo IV), from positions 67-106 [50). Mutation of amino acid positions 83 and 87 (of 
GyrA) is often associated with clinical resistance [51] and is known as the quinolone resistance 
determining region (QRDR) [52] and is located within the DNA binding interface of gyrase. 
Fluoroquinolone antibacterials known to bind to both DNA and the topoisomerase IV with 
amino acids in the QRDR form a binding s ite. Obviously, mutations in this region resu lts in 
decreased affinity fo r fluoroquinolone binding followed by decreased activity leading to 
resistance [53). 
1.3 DNA, DNA super coiling, replication and topoisomerase 
DNA is a prominent macromo lecule among four macromolecules (nuc le ic ac ids, proteins, 
carbohydrates and lipids) which are crucial fo r all forms of life. DNA carries genetic information 
in a series of nuc leobases (guanine, adenine, thymine, and cytosine) denoted by letters G, A, T , 
and C. In fact, DNA is a polymer of deoxyribose nucleotides, which fundamentally composed of 
a nitrogenous base, a five-carbon sugar (deoxyribose) and phosphate groups. It functions as 
genetic carrier of a ll known liv ing organisms and many viruses. It also allows mutation and 
recombination and serves as a template for semi-conservative repl ication [54]. The polymer is 
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linked by phosphate groups and hydrogen bonds between nucleotides of opposing chains 
(strands) form a double helical structure. Usually, DNA is found as double-stranded helices, 
composed of two long polymers of simple units called nucleotides. DNA is well-equipped for 
storing biological information, since the double-stranded structure provides the molecule with an 
replica of the encoded data. Followings here are some basic characteristics of DNA molecule and 
its orientation in the nucleus. 
1) In the E. coli bacterium, the DNA is approximately I 000 11m long [55], as compared to 
the cell which is 1-2 ~J.m. In order to accommodate such elongated strand of DNA in a 
relatively small cell, it must be highly condensed. Thus, the chromosomal DNA is 
coiled around itself in purported supercoiling. The supercoiling facilitates this 1000 ~Lm 
long chromosome to accommodate within the cell with an actual girth of about 1 ~J.m. 
Despite its super condensation state, DNA is always able to replicate, and allows 
transcription of the individual strands as required without becoming fatally entangled. 
2) Usually DNA possesses double- helical structure. With each turn of a helix, two single 
strands are winding with each other. On an average around I 0.4 base pairs separates two 
consecutive turns of DNA. Likewise, an E. coli chromosome composed of 4 million base 
pairs. This suggests that essentially the E. coli chromosome must be intertwined about 
400,000 times. This double helical structure must unwind by the same number of times 
whenever DNA undergoes semi-conservative replication. 
3) Prokaryotic DNA differs from eukaryotic DNA in many instances. Prokaryotic DNA 
undergoes less than one turn for each I 0.4 base pairs [56] leading to negative 
supercoiling of DNA. Negative supercoiling is a fundamental characteristic of 
prokaryotic DNA to ease DNA replication and transcription and the who le process 1s 
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done with the help of the energy of the cell in the form of ATP. In summary, the creation 
and maintenance of negative supercoiled state of DNA uses a tremendous amount of 
energy. 
4) Replication and transcription of DNA requires its helical structure to be unwound into 
two separated parallel strands facilitated by several enzymes to make the unwinding 
possible. RNA polymerase is one amongst those enzymes. RNA polymerase binds to the 
DNA and, with other cofactors, unwinds the DNA to create an initiation bubble so that 
the RNA polymerase can access to the single-stranded DNA template. However, 
unwinding during D A replication means generation of positive supercoils ahead of the 
replication fork [57-60].Generation of positive supercoils is also a highly energy 
consuming process. Uninterrupted generation of positive supercoils causes scarcity of 
energy with in the cell and eventually it becomes difficult for RNA polymerase to unwind 
the DNA and carry out transcription, in energy deficient environment. This generation of 
positive supercoils, if not resolved, will lead to inefficiency in the transcription and 
rep I ication processes. 
The process of generation of positive and negative supercoils is well regulated by a group 
of enzymes known as Topoisomerases [56, 61-63]. This group of enzymes fix the number 
of times one single strand of D A duplex winds around its complementary strand. 
Fundamentally, we can assume that these enzymes are crucial for cell growth and 
rep I ication. 
Three members in this group of topoisomerase enzymes have been discovered so far are 
categorized as: 
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1) Type I Topoisomerase - represented by topoisomerase I (in both eukaryotes and 
prokaryotes) and Ill in prokaryotes. 
2) Type H Topoisomerase - represented by DNA gyrase (bacterial topoisomerase II and 
mammalian topoisomerase II) and Bacterial topoisomerase IV. 
3) Special Topoisomerase - represented by those catalyzing transposition. 
1.3.1 Bacterial Topoisomerase I 
Topoisomerase I was discovered by James Wang in 1969 from E. coli [64]. Type 
I topoisomerase is a II 0-kDa protein and is encoded by the tapA gene [65]. 
Type I topo isomerase breaks one strand of DNA and passes it through the other. 
Topo isomerase I (bacteria l as well eukaryotic), were able to release negative supercoils 
from DNA, even in the absence of A TP [64]. On the other hand, eukaryotic 
topoisomerase I was also able to remove positive supercoils. In a prokaryotic cel l, DNA 
gyrase and topoisomerase I, both regulate the negative super- coiling of DNA [66, 67] 
and hence these enzymes are essential for transcription to take place [68]. Pruss et al. 
conducted a study on tapA mutants of E coli [69]. These mutants were not able to 
produce a functional topoisomerase enzyme. This incident defers by excessive 
accumulation of negative supercoils in plasmid pBR322 DNA of tapA mutant bacteria. 
This excessive accumulation of negative supercoils was dependant on transcription of tet 
gene. Hence, this study proved that topoisomerase I is required for removal of negative 
supercoil behind the progressive transcriptional bubble. 
In general, quinolones inhibit the DNA relaxation activ ity of topoisomerase I at very 
high concentrations only [70, 71 ]. 
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1.3.2 Bacterial topoisomerase II (DNA gyrase) 
DNA gyrase was first isolated by Martin Gellert and associates in 1976 from E. 
coli bacterium [56, 61-63, 72]. Based on high reso lution microscopy, it was confirmed 
that gyrase had a heart shaped structure [73]. DNA gyrase is made up of four different 
subunits comprising of two A subunits (GyrA) and two B subunits (GyrB) [74, 75]. The 
GyrA subunit is encoded by the gyrA gene and GyrB subunit is encoded by gyrE gene. 
Both GyrA and GyrB subunits have specific functions. GyrA subunit is mainly required 
for DNA cleavage and re-ligation using a specific tyrosine residue (Tyr-1 22), which 
forms a temporary phosphotyrosine bond with the broken strand of DNA. GyrB subunit 
controls A TPase activity of the enzyme [75]. Several research studies have been 
conducted using the fragments of GyrA and GyrB subunits to scrutinize various 
functional domains of these subunits. 
Reece eta!. found out that the addition of a C-terminal 33-kDa GyrA fragment improved 
the efficiency of the enzyme and was able to stabilize the complex [76]. A 47-kDa C-
terminal fragment of GyrB, when complexed with the GyrA subunit, was able to cause 
DNA relaxation but not A TP hydrolysis. Further work was subsequently carried out to 
identify the A TP binding site in the gyrase enzyme. The N-terminal region (amino acid 2 
through 220) of the GyrB subunit is now considered as ATP binding region [77]. This 
finding is based on the study of the x-ray crystallographic structure of the gyrase enzyme. 
The structure of the gyrase enzyme complexing with the DNA has been studied 
extensively [73, 78]. It was found in those studies that a sing le turn of DNA is wrapped 
around the enzyme. A TP, when bound to the GyrB subunit, was able to induce structural 
change to the enzyme which eventually results in increased superco iling [78]. In other 
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words, A TP is required by the gyrase to function [79]. DNA gyrase also requ1res a 
divalent cation (mainly magnesium) to function. Replacement of magnesium with 
calcium has been shown to result in an abortive DNA breakage reaction [76]. 
1.3.3 Bacterial Topoisomerase III 
Srivenugopal et al. discovered topoisomerase Ill in 1984 [80] . This enzyme can 
remove the negative supercoils in DNA without energy consumption, but it needs energy 
in the form of A TP to remove positive supercoils [80]. On the other hand, it is less 
efficient as compared to other types of topoisomerase (8 1]. Topoisomerase Ill has affinity 
for both DNA, as well as RNA [82]. It is encoded by the topE gene located at 38.7 min 
on the E. coli genetic map [83]. Studies were conducted on mutants where genetic 
information was removed from 38.4 min to 39 min. Survival of these mutant bacteria 
have proved that topoisomerase Ill enzyme is a non-essential enzyme (83]. 
1.3.4 DNA Gyrase: primary target for quinolone action 
In 1977, GyrA subunit was reported as a primary target of nalidixic and oxolinic 
acids by Gellert [84] and Cozzarelli [85]. Research has been done on purified gyrase 
enzyme in which GyrA subunit was collected from nalidixic acid resistant mutants and 
GyrB subunit was derived from the wild type population. Th is modified enzyme was 
active in the presence of normal concentrations of nal idixic acid that inhibited the wild 
type enzymes. Same experiments were repeated for B. subtilis (86], Enterococcus 
faecalis [87], S. aureus [88], Pseudomonas aeruginosa [89-92], and Haemophilus 
injluenzae (93]. These experiments endorsed the same assertion that the GyrA subunit is 
also a target of quinolone action. 
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Two different mutations identified on the gyrE gene that are responsible for nalidixic acid 
resistance [94-96]. The first one, was responsible for increased resistance to newer 
quinolones. The second one caused increased susceptibility to quinolones containing 
piperazine at the C-7 position [97]. These studies confirm that both GyrA and GyrB 
subunits are targets for quinolone action. 
The quinolone binds to the DNA - DNA Gyrase complex and blocks the religation of the 
cut DNA strands [98]. The ternary complex forms a "roadblock" for the replication 
machinery. Quinolones exert their inhibitory effect by binding to the Gyrase-DNA or 
Topoisomerase IV- DNA complexes. Upon binding with the complex, quinolones induce 
a conformational change in the enzyme. As a result of this conformational change, gyrase 
can still break the strands of DNA but loses its ability to re-ligate it (Figure 1.9). The 
overall result is the formation of a quinolone-enzyme- DN A complex. This complex 
formation reversibly inhibits DNA and cell growth and is respons ible for the 
bacteriostatic action of the quinolones [97, 98]. 
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Figure 1.9. DNA gyrase super coiling cycle showing the point of action of quinolones [98] 
(Reproduced with permission from copyright holder; see appendix A-1 for details) 
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Conclusion 
Antibiotics are Chemicals which kill and/or stop the growth of bacteria and other 
microorganisms. These drugs may be of natural origin or may be synthetic 
depending on their source. In synthetic antibiotics, the quinolone molecule is one 
of the most promising scaffold which can be customized in several ways to achieve 
a wide range of pharmacological activities. These activities can range from being 
antibacterial, anti-ischemic, antitumor or antiviral. Due to emerging bacterial 
resistance to existing antibacterial agents, the discussion on quinolones in 
antibacterial research is still an extremely important topic. 
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2.1 Structure-Activity Relationships of Quinolones 
Biological activity of a compound depends upon its structural feature which is responsible for 
interation with a specific receptor. Structure-Activity Relationships (SAR) is a comprehensive 
review on structural modifications of a specific class of biologically active compounds in order 
to improve or optimize some critical factors such factors include potency, efficacy, 
pharmacokinetics/pharmacodynamics, and safety aspects of that class and, as a result, 
identification of a lead compound for further preclinical studies. Fluoroquinolone skeleton is 
well studied by various researchers, in order to find the role of a specific substitution and effect 
on receptor. Figure 2.1 comprehensively explains the role of various substitutions on the 
fluoroquinolone pharmacophore and its impact on microbiological activity of the respective 
compound. 
Position-! 
Anti bacterial activity against Gram-negatives decreases when substitution at N-1 position is an 
alkyl or arylmethyl moiety, while the same structural pattern causes an increase in the activity 
against Gram-positive bacteria [I ,2]. On the contrary, activity is retained with the addition of 
fluorine atom to the substitution at the N-1 position [3]. These studies also assert 2, 4-
ditluorophenyl as the second most important moiety at this position to improve the antimicrobial 
activity of quinolones [4]. 
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Figure 2.1. General structure of most commonly used quinolone molecules. 
(Reproduced with pe rmission from copyright holder; see appendix A-2 for deta ils) 
Position-2 
Before the discovery of fluoroquinolones, substitution at this position of a quinolone nucleus was 
reported to cause diminishing or loss of antibacterial activity [5]. As this position is in proximity 
to the gyrase binding site, various large substitutions at this position were considered to hamper 
the transfer of quinolones across the bacterial cells which ultimately results in reduction of 
antimicrobial activity [I). Even addition of a small substitution such as methyl group at this 
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position was reported to result in complete loss of antibacterial activity. These results give us an 
inkling of another phenomenon that a large substitution at this position impedes the interaction 
between DNA gyrase and drug molecule by interfering with the co planarity of the C-3 carboxyl 
and C-4 keto groups of quinolone ring. However, when sulfur is incorporated in a small ring to 
replace the hydrogen, the antibacterial activity is reported to be retained [I]. During the synthesis 
and antibacterial evaluation of norfloxacin analogues, it was observed that the antibacterial 
activity was retained when nitrogen replaced carbon at the position 2while potency was 
significantly decreased. This can be inferred from comparative MIC values in Table 2.1 [6, 7]. 
Table 2.1. MIC ofC-2 variants 
0 
Drug X MIC (11g/ml) 
against E. Coli 
Norfloxacin CH 0.1 
-- N 3.1 3 
Positions-3 and -4 
Positions 3 and 4 handle the gyrase binding and bacterial transport processes. A carboxyl 
substitution is found to be superior compared to the esters, phosphonates and sulphonates [8]. In 
the same fashion, a fused thiazolidone ring at the C-2 and C-3 positions of quinolones 
demonstrates analogy to a carboxylic acid group because of its aromatic resonance, and results in 
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compounds with outstanding in vitro potencies. Comparative MIC values against vanous 
bacterial strains are shown in Table 2.2 [9-11 ]. 
A 
Table 2.2. MIC of C-3 variants 
Structure MIC (j..tg/ml) DNA gyrase IC5o 
E. coli P. aeruginosa S. aureus (j..tg/ml) 
C i profl oxaci n 0.004 0.125 0.25 0.3 
Compound A 0.005 0.02 0.02 0.09 
Position-5 
Substituents at this position form hydrogen bond with DNA. So this substituent must not be 
colossal or sterically hindered, and should be able to form hydrogen bond with the DNA fo r 
increased potency [ 12]. Antimicrobial activity against E. coli was found to increase after the 
addition of a primary amine substitution at C-5 [ 12]. Some electron-donating groups, for 
example hydroxyl, methyl etc., were also noticed to increase in vitro activity against Gram-
positive bacteria. See Table 2.3 forMIC data [ 13]. 
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X 
NH2 
OH 
F 
Position- 6 
F 
H2N~ 
s 
X 
F 
COOH 
N 
L 
Table 2.3. M IC of C-5 variants 
MIC (~tg/ml) for: 
E. coli P. aeruginosa 
0.025 0.1 
1.56 6.25 
0.78 3.13 
S. aureus 
0.05 
1.56 
3. 13 
Afte r the discovery of fluoroquinolones, the fluorine substitution at this position was fo und to be 
essential for the antibacterial activity as shown in Table 2.4 [ 14]. In this context, Ledoussal et al. 
[ 15] were able to co nfirm the above phenomenon by making several C-6 fluorinated quinolones 
and compare their antibacterial profile with those molecules lacking the C-6 fluorine substituent. 
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COOH 
Table 2.4. MIC of C-6 variants 
MIC (1-lg/ml) for: 
R E. coli P. aeruginosa 
H 0.78 3.13 
F 0.05 0.39 
Position-7 
This position controls potency and pharmacokinetics of the compounds. Also, it is involved in 
direct interaction with the DNA gyrase [ 16] . Five- or six-membered nitrogen heterocyclic 
moieties (piperazinyl, N-methylpiperazinyl, pyrollidinyl, etc.) are the most common substituents 
at this position. 
Position- 8 
Substituents at this position contribute not only to pharmacokinetics properties of drug molecule 
and spectrum of activity but also play a ro le in reducing the development of bacterial resistance 
so 
[ 17]. Alkylation at this position is favourable since it not only improves the antibacterial activity 
against Gram-positive bacteria; it also improves the overall pharmacokinetic parameters. 
2.2 Uses of Quinolones 
2.2.1 Quinolones as Antitumor Agents 
Cancer, the second largest cause of mottality in the world, is continuing to be a maj or health 
problem in the developed as well as deve loping countries. Tumor cells divide in an uncontrolled 
manner as compared to the other normal body cells. Human topoisomerases are of key 
importance in DNA replication and play important ro les in cleaving the DNA chain at a 
particular point to reduce the stress of the growmg replication fork and also simplify the 
annealing of the separated stra ins once replication has been done . Inhibition of these enzymes 
affects the vital functions of cell and more specifically arrests the cell cycle. Many 
topoisomerase directed cytotoxic agents are developed based on the idea of targeting human 
topoisomerases [ 18]. 
As described in Chapter-! of this thesis, human topoisomerase II is analogous to DNA gyrase of 
prokaryotic organisms. Traditional targeting agents of this enzyme like the natural pentacyc lic 
alkaloid and camptothec in, usua lly binds to topoisomerase II and forms a stable binary DNA-
topoisomerase complex. This complex is composed of a single-strand nick thereby inhibiting 
DNA replication and ultimate ly arrests cell growth causing cell death during the S phase of the 
cell cycle. Many compounds like teniposide, etoposide, adriamycin etc., target topoisomerase II 
to exert their cytotoxic profile [ 18]. DNA intercalating agents, which are wel l established in the 
treatment of cancer, are a lso known to cause DNA damage as a mode of their cytotoxic action 
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[ 18 19). Various studies have revealed that topoisomerases are involved in mediating the effect 
of various cytotoxic drugs, including DNA intercalating agents [ 18, 19). 
Since the past two decades, quino lones have earned a special place in the treatment of infectious 
diseases due to their antibacterial activity as they cause potential chromosomal DNA damage 
within the bacterial cells [20, 2 1 ). Further research found that fo rmation of gyrase-DNA 
complexes g ive rise to the development of extra quinolone binding pockets which further bo lster 
the mechanism of DNA damage [22]. Most quinolone derivatives have very. high specificity fo r 
the enzyme such as bacterial or human topoisomerase. However, these enzymes are homologues 
so there is a great possibility of interaction with both enzymes by some compounds. Indeed, 
several antibacterial quino lones that also inhibit P4 DNA- unknotting activity of vanous 
eukaryotic type II topoisomerase have been identified [23-25]. 
Another study done by Kohlbrenner et al. [26] has reported two novel antibacterial 
isothiazoloquinolones, A-6528 1 and A-65282 (F igure 2.3) wh ich target both bacterial and 
eukaryotic topoisomerases. These compounds were shown to induce DNA strand breakage as 
well as to inhibit the P4- unknotting reaction catalyzed by calf thymus topoisomerase II. This 
study, again, introduces a new class of topoisomerase II directed compounds, which were able to 
interact with both bacterial and eukaryotic enzymes. 
Robinson et al. [27] reported CP-115,953 which shows twice as much potency as that of 
etoposide at enhancing topoisomerase II mediated DNA c leavage. When the cyclopropyl group 
was replaced with an ethyl group at N-1 position, potency was found to be reduced by 20%. 
Compound WIN 57294 [28), A-62176 [29], and A-85226 [30) were a lso found to be effective 
against cancer cell growth. Compound A-65282, which is an isothiazo loquinolone derivative, 
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was reported to demonstrate comparable potency to that of teniposide tn enhancing 
topoisomerase 11-facilitated DNA breakage. Compound WIN 57294, which IS a 7-(2, 6-
dimethyl-4-pyridyl) derivative, was found to have an EC50 value of 7.6 JlM in a DNA cleavage 
assay using HeLa topoisomerase II. Compound A-62176 and A-85226 were found to have broad 
activity against human and murine tumour cell lines. Compound AG-7352 [3 1] was also found 
to be more cytotoxic against human cell lines as compared to etoposide. 
_S_ignal !ransducers and ~ct i vators of !ranscription (STATS) are proteins which are responsible fo r 
modulation of signals and transcription in the cell. Yinkemeier et a/. have defined them as "A 
family of transcription factors that are specifically activated to regulate gene transcription w hen 
cell s encounter cytokine and other growth factors" [32]. By this encounter, STA TS regulate 
several processes that drive tumorigenesis, including proliferation, cell surv ival and 
angiogenesis, and also play an important role in immune surveillance. There are seven members 
in the STA TS family discovered so far. Out of those seven different subtypes of mammalian 
STAT protein, STAT3 and STAT5 are oncogenic STA TS which are constitutively activated in a 
variety of tumors. STAT I, whose function is assumed to antagonize the activities of STA T3, 
possesses tumor suppressor properties. Therefore, this protein has a discrete place in anticancer 
therapy as its expression has been shown to be reduced in several types of tumors. A lso, ST A T3 
has achieved a pivotal position as a target in anticancer therapy [33]. 
A recent high throughput screening [34] carried out on large number of compounds found that a 
highly fluorinated quinolone derivatives, inhibits STA T3 pathway and causing apoptosis (EC50 = 
4.6JlM). Around 30 percent increase in STA T3 pathway inhibitory potency has been noticed by 
further optimisation of the structure of this fl uorinated compound (Figure 2 .2) [34]. 
53 
F 0 
F COOEt 
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Figure 2.2. Structure of highly fluorinated quinolone derivative 
Fertile results encourage researchers to perform a receptor-based virtual screening on a large 
array of compounds (around 70,000 different compounds). The results have revealed that some 
of the 3-carboxy-4( I H)-quinolones have very powerful human protein kinase CK2 inhibitory 
activity [35]. Protein kinase CK2 plays a significant role in the progress of various types of 
cancer and has been also demonstrated to play a pivotal role in viral infection and inflammatory 
processes. The chemical structures of the above mentioned compounds are depicted in Figure 2.3 
[35]. 
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Figure 2.3. Structures of novel quinolone derivatives having anticancer activity 
2.2.2 Quinolones as Antiviral Agents 
2.2.2.1 Quinolones as HIV-1 Inhibitors 
Despite the availability of several classes of anti-H IV agents, there are limitation of options on 
therapeutic agents with sustained activity and reasonable efficacy against this vi ral infection. 
One of the most important limitations is the rapid emergence of resistant strains and inability of 
current treatment regimens to completely eradicate viral infection. To circumvent these problems 
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researchers are working towards devising novel molecules possessmg new mechanisms of 
action, which are assumed to be a solution for these short- comings. Viral replication is again a 
set of reactions, one and most important of which is the transcription of its genome into mRNA. 
Most of the antiviral agents act by inhibiting this step which eventually leads to suppress HIV 
replication in both acutely as well as chronically infected cells [36]. Baba and coworkers 
suggested for the first time that some antibacterial fluoroquinolones can also exhibit antiviral 
activity. Two analogues, K-37 and K-38 (Figure 2.4), having a 3, 4-dehydro-4-phenyl-1-
piperidinyl moiety at the C-7 position, exhibited EC50 < 50 nM in chronically infected cells. 
Cecchetti and coworkers [37] began a study on various quinolone derivatives including 6-
fluoroquinolones and 6-desfluoroquinolones, and discovered that 6-amino-1-tert-butyl-7 -[ 4-
(pyridin-2-yl)]-1-piperazinyl-4-oxo-1 ,4-dihydroquinoline-3-carboxylic acid exhibited good 
antiviral activity and was taken as the lead molecule. To establish the structure-activity 
relationships of this lead, a series of variously substituted molecules were synthesized. Among 
those molecules, Compound 24 (Figure 2.4), which has a methyl substitution at the N-1 position 
and a 4-(2-pyridinyl)-1-piperazine moiety at position 7, was found to be the most potent 
molecule with EC5o = O. lj.!M. 
0 0 
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Figure 2.4. Structure of K-37, K-38 and compound 24 
2.2.2.2 Quinolones as HIV-1 Integrase (IN) Inhibitors 
Three most important enzyme encoded by the HIV-1 viral genome are: I) HIV-1 reverse 
transcriptase; 2) HIV-1 protease; and 3) HIV-1 lntegrase. 
HIV-1 lntegrase (IN), integrates viral eDNA into the genome of the host cell [38]. The insertion 
reaction catalyzed by IN involves two different steps. First step, usually takes place in the host 
cell cytoplasm and in this step IN cleaves GT nucleotides from the conserved 3'-CAGT motif. 
This reaction is known as 3' processing and produces unprotected hydroxyl groups at the both 3' 
ends of viral eDNA. The processed viral eDNA along with IN then moves to the nucleus of the 
host cell , where the second reaction takes place. In the second step of the integration, IN 
facilitate the nucleophilic attack of both 3'-end hydroxyls of the viral eDNA onto the host DNA. 
This process is usually termed as the strand transfer reaction. 
The diketo acid (DKA) c lass of IN inhibitors were the first milestones for the inhibition of IN. 
For example, Raltegravir has wide spectrum of activity as an IN inhibitor. Recently discovered 
57 
GS-9137 (Figure 2.5) [39], which is a derivative of 4-quinolone-3-carboxylic ac id, is fo und to be 
effective as an IN inhibitor, and is currently under clinical evaluation [40]. 
GS-9137 Raltegrav ir 
Figure 2.5. Structures of GS-9137 and Raltegravir 
2.2.2.3 Quinolones as Anti-HSV-1 Agents 
Herpes simplex virus (HSV) is globa lly a very common pathogen for van ous infections. 
Predominantly, HSV-1 causes infections on the face and lips, w hich inc ludes cold sores and 
fever. Conventionally, acyclov ir is widely used as a chemotherapeutic agent for the treatment of 
these infections or lesions. Unfo rtunate ly, development of res istance against the effect of 
acyclovir in immune -compromised patients is the most encountered problem[ 4 1 ]. Recent 
research for quino lone-based derivatives that can be used in treating HSV -I infections 
discovered Compound 23 (Figure 2 .6). It is a quino lone acyclonucleoside derivative which has 
shown reasonable activity against HSV -1 [ 41 ]. At the concentration of 50 jlM, this compound 
has demonstrated efficacy in reducing the vira l load in the range of 70-99%. In the same 
research, it was fo und out that the carboxylic acid derivatives of quino lones were more effective 
than their corresponding esters. Various other structure analogues of compounds (23) were also 
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tested for cytotoxicity m Vero cells. Recently discovered quinolone derivatives were found 
effective in preventing the cytopathogenic effect of HSV -I at 11M concentrations. Among all , 
Compound 23 was found to be the most effective anti-HSV -I derivative with almost 1.5-fold 
potency as that of acyclovir. 
Further screening of latter compounds and a naphthalene carboxamide derivative have revealed 
the inhibitory activity of these non-nucleoside molecules against human cytomegalovirus 
(HCMV) polymerase. PNU-183792 (Figure 2.7) acts as a competitive inhibitor of herpes virus 
polymerase which was effective against both human and animal herpes viruses. However, when 
toxicity assays were performed on PNU-183792 using four different mammalian cell lines, the 
results were not encouraging enough for cytotoxic activity at relevant drug concentrations (CC 5o 
value > I 0011M). 
Compoun d 2 3 
Figure 2.6. Structures of Acyclovir and compound 23 
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Figure 2.7. Structure of PNU-183792 
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2.2.3 Quinolones as Anti-Ischemic Agents 
Ischemia occurs when partial or complete blockages of coronary arteries hamper the blood flow 
to the heart muscle. This type of ischemic cell injury further contributes to fatality or life-long 
disability. Thrombolytic therapy is the most common treatment for ischemic cell injury to 
overcome this obstruction. Thrombolytic agents help to restore blood flow to the ischemic 
region. However, thrombolytic therapy is also endowed with various limitations. Lately, on-
goi ng research on a few antibiotics has found them to be potential anti- ischemic agents. 
Antibiotics are used to treat inflammation and/or infection linked to ischemia; hence they can be 
viewed as prospective anti-ischemic agents [42]. Park eta!., has proposed in his research that 
ciprofloxacin exhibited in vivo and in vitro anti-ischemic activity. Lead optimization study on 
various known and novel molecules, with an obj ective to differentiate anti-ischemic activity 
from the anti-bacterial activity, resulted in the discovery of SQ-4004. This compound exhibited 
potent cell v iability in addition to neuroprotective as well as cardioprotective effects. On the 
other hand, the antibacterial activity of this compound was reduced.(Figure 2.8) [42]. 
COOH COOH 
Ciprofloxacin SQ-4004 
Figure 2.8. Structures of Ciprofloxacin and SQ-4004 
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2.2.4 Quinolones as Anxiolytic Agents 
Anxiety can be defined as disturbances in psychological and physiological state which are 
characterized by somatic, emotional, cognitive, and behavioural components [43]. In order to 
maintain normal well-coordinated activity, there are two types of neurotransmitters found in the 
CNS, namely excitatory and inhibitory. y-aminobutyric acid (GABA) is one of the most 
important amongst a ll inhibitory neurotransmitters in the central nervous system. It exhibits its 
effects by acting primarily on GABA receptors. Structurally, GABAA receptor composes of a 
pentameric macromolecular complex which regulates the opening and closing operations of 
ligand-gated chloride ion channels. In humans GABAA receptors are made up of six types of a 
subunits, three different types of~ and y subunits as well as a o and e subunits. Each of these 
subunits has different functions which are implemented via different phys iological effects (for 
example a 1-containing receptors are involved in sedation, a 2 and a 3 in anxiolytic activ ity) [44]. 
The benzodiazepine class of drugs has been w idely used as anti-anxiety agents for a long time. 
Benzodiazepines are non-selective against the receptors on which they act and a llosterically 
control the GABA-mediated chloride ion influx through the ch loride ion channel. On the 
contrary, benzodiazepines cause considerable amount of adverse effects. This problem incited 
the need of better anxiolytic agents. 
A study carried out by Kahn berg et a/. [ 45] found that 3-ethoxycarbonyl-6-tritluoromethyl-4 
( I H)-quinolone (15) was a very fruitfu l lead compound for developing novel molecules that can 
effectively bind to the binding site of benzodiazepines on GABAA receptors. Further 
optimisation of this compound led to a large number of novel molecules that were able to bind to 
GABAA receptors with very vibrant affinity. However, in this study only compounds 20-22 were 
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tested on the a1P2Y2s and a3P2Y2s GABAA receptor subtypes. Compounds 21 and 22 were found to 
be selective for a 1_ vs. a3-containing receptors. The Ki ratio for compounds 21 and 22 was found 
to be 22 and 27, respectively. These values for receptor selectively were found comparable to 
that of the well known a 1 subunit selective drug, Zolpidem. Structures of compounds 15-22 are 
0 0 
shown in Figure 2.9. 
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Figure 2.9. Novel qu inolone derivatives with anti-anxiety effect 
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2.3 Thiazetoquinolones 
2.3.1 Introduction 
Like most of the currently utilized antibacterial agents, emerging bacterial resistance, especially 
methicilline-resistant Staphylococcus aureus (MRSA), has become a major barrier in 
chemotherapeutic application of different generations of quinolones. Thus the need for more 
effective agents to treat infectious diseases caused by drug-resistant bacteria, such as quino lone-
resistant MRSA, is essential [46, 47]. 
While searching for new quinolone antibacterial agents scientists came across a tricyclic sulfur-
containing quinolone derivative in which a 4-( I H) quinolone system is fused to a thietane ring at 
N-1 and C-2 junctions (Figure 2.1 0). This building block was later named thieazetoquinolone 
[46, 48]. 
( 4 (1 H)-<:Jui nolon~ 
[ Thietane] Thiazetoquinolon 
Figure 2.10. Thiazetoquinolone nucleus 
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2.3.2 Some structural features of thiazetoquinolones 
As discussed in SAR of quinolones, any polycyclic structure with a bridge connecting the N-1 
and C-2 positions of the quinolone would prevent the free rotation of the substituent attached to 
the C-2 position, thereby affecting the interaction of these compounds with topoisomearase II. 
Researchers expect that such structure should retain its activity against DNA gyrase [48]. In this 
context, M. Matsuoka et a/. were able to synthesize a series of compounds and noted the 
excellent antibacterial activity In 6-fluoro-1-methyl-4-oxo-7-( l-piperazinyi)-4H-[ I ,3] 
thiazeto[3,2-a ]quinoline carboxylic acid (Figure 2.11) [ 49]. 
0 
Figure 2.11. Structure of 6-fluoro-1-methyl-4-oxo-7-( l-piperazinyi)-4H-[ I, 3] thiazeto[3,2-
a]quinoline carboxylic acid. 
Generally, substitution of a cyclic amino moiety at the C-7 position of a quinolone scaffold plays 
an important role in antibacterial potency of these molecules. This phenomenon is also 
applicable in thiazetoquinolines when the C-7 position of this scaffold is substituted by a 3-
hydroxyazetidinyl moiety. In fact, the 3-hydroxyazetidinyl-substituted derivative displays the 
best activity against Gram-positive bacteria amongst all other counterparts including morpholinyl 
, piperazinyl, and thiomorpholinyl analogues. An analogue with piperidine substitution has 
shown least activity amongst all [ 49, 50]. The same authors also synthesized some 8-
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unsubstituted-1-fluoromethylthiazetoquinolone derivatives, among which, 7-(3-
hydroxyazetidinyl) analogue was showing the most significant antibacterial activity against 
Gram-positive bacteria including MRSA. The 7-(4-methyl-1-piperazinyl) analogue and 7-
morpholino analog showed considerable antibacterial activity against Gram-positive resistant 
bacteria, whereas other analogues like 7-(3-hydroxyazetidinyl) analogue showed no significant 
activity [49). 
On the other hand, the order of in vitro activity against Gram-negative bacteria was completely 
different. The analogue with 4- methyl piperazinyl and piperazinyl substituents were showing 
very good activity amongst all. Whereas, the analogue with thiomorpholinyl or 4-
hydroxypiperidiny l and also 4-aminomethylpiperidinyl moieties showed the lowest activity [ 49, 
50]. Among all the derivatives prepared by M. Matsuoka et al, 7-piperazinyl analogues were 
found to exhibit the most balanced in vitro activity against both Gram-positive and Gram-
negative bacteria including quinolone-resistant MRSA [49). 
Insertion of a fluoromethyl moiety at the C-1 position of thiazetoquinolone ring also influences 
profile and antibacterial potency of this class of compounds. In the 8-unsubstituted-7 -( 4-methyl-
1-piperazinyl) derivatives, 1-fluoromethyl analogue was showing more potent 
antibacterialactivity against quinolone-resistance MRSA as compared to 1- methy l analogue, but 
exhibiting the same or less activity against other bacteria. Whereas, in the 7 -( 1-piperazinyl) 
derivatives, the substitution of fluoromethyl at C-1 position did not affect its potency against 
Gram-positive bacteria, it even decreased activity against Gram-negative bacteria 
considerably[ 49). Methoxy group at C-8 position of the 1-fluoromethyl analogue resulted in 
moderate increases in antibacterial activity against Gram-positive bacteria including quinolones-
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resistant MRSA.The addition of fluorine at C-8 position led to decreased antibacterial activity 
(Figure 2.12) [ 49]. 
0 
F 
R X Gram-positive MIC(~g/ml) Gram-negative MIC {Staphylacoccous aureus) (~g/ml) {E. Coli) 
4-Methylpiperazinyl H 0.1 0.05 
4-Methylpiperazinyl MeO 0.05 0.025 
4-Methylpiperaziny l F 0.2 0.2 
Piperazinyl H 0.05 0.025 
Cis-3,5-dimethylpiperazinyl H 0.1 0.05 
Morpholino H 0.05 0.2 
Thiomorpholino H 0.1 0.78 
4-Hydroxypiperidino H 0.05 0.2 
4-Aminopiperidino H 0.1 0.2 
4-Hydroxymethylpiperidino H 0.1 3.13 
4-Aminomethylpiperidino H 0.2 1.56 
3-Hydroxyazetidino H <0.00625 0.05 
4-Methylpiperazinyl H 0.2 0.1 
4-Methylpiperazinyl H 0.025 0 .0125 
Figure 2.12. In vitro antibacterial activity ofThiazetoquinolone derivatives 
2.4 Conclusion 
The quinolone nucleus is one of the most prom1smg scaffolds which can be modified in a 
number of ways to ach ieve diverse pharmacological activity. Huge array of activities including 
antibacteria l, anti-ischemic, antitumor, antiprotozoal, antihelminthic and antiviral have been 
displayed by this class of compounds. Despite decades of research on their activities, it is still a 
hot topic for researchers. Even after discovery of involvement in various activities, there are still 
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a lot of unsolved problems to resolve due to development of resistant bacterial strains or 
unexpected adverse effect profiles of the existing regimens. 
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Chapter-3 
Design, Synthesis and In-vitro 
Evaluation of thiazeto [2,3-
a]quinolones as Potential 
Bioactive Molecules 
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3.1 Introduction 
As discussed in Chapter 2 of this thesis, quinolone derivatives can act as anticancer agents. 
Anticancer quinolones cause cytotoxicity through DNA intercalation or by causing interference 
in the replication process. As mentioned in Chapter- I of this thesis, human topoisomerase II is 
analogous to DNA gyrase enzyme of prokaryotic organisms. Some antibacterial or anticancer 
quinolones such as actinomycin D, doxorubicin, mitoxantrone and streptonigrin display their 
biological activities through DNA intercalation [I]. Despite the vast number of quinolone 
analogues reported with reasonable biological activity, researchers are still delving into this field 
for synthesis of new compounds with a novel structure and different mechanisms of action. Due 
to bacterial antibiotic resistance and toxicity profiles of compounds, research is moving towards 
the extension of quinolone genera with formation of novel polycyclic quinolone analogues with a 
good biological activ ity and less toxicity. 
Our research group has long been involved in developing a novel series of polycyclic quinolones 
with diverse biological activities [2a-c]. In this context our previous group member, Dr. Abeer 
Ahmed, was able to isolate and identify novel 4-oxo-benzo[h]thiazetoquinoline derivatives [3] 
(Figure 3. 1 ). The discovery of this compound was considered as serendipity due to unexpected 
structural feature of the product while attempting to synthesize a thieno [2 ,3-b ]benzo[h]quinoline 
derivative. While there are numerous research reports available on various polycyclic 
quinolones, for example 4-oxo-thiazolo [3-2a]quinoline-3-carboxylic ac id derivatives, 4-oxo-
thieno[3,2-a] quinoline 3- carboxylic acid derivatives etc., there are very limited reports on the 4-
oxo-thiazeto [3, 2-a] quinolines [4-7]. The research reported by Dr. Ahmed prompted us to 
continue our research on 4-oxo-thiazeto[3 , 2-a]quinolines. 
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Figure 3.1. 4-oxo-benzo[h] Thiazeto[3,2-a]quinoline derivatives [2a] 
An extensive literature search on the chemistry of thiazeto[3,2-a] quinolines led us to a series of 
publications related to the synthesis and antibacterial activity of a 4-oxo-thiazeto[3 ,2-a] 
quinoline-3-carboxylic acid, Prulitloxacin [8] (Figure 3.2). Actually, it is a prodrug which 
metabolizes in the body to the active compound ulitloxacin [9]. The first synthes is of this 
compound was reported almost two decades ago by Nippon Shinyaku Co. and patented in Japan 
in 1987 and in the United States in 1989. [I 0-13] 
F 
Figure 3.2. Structure of prulifloxacin 
As discussed in Chapter 2 of this thesis the rationale for prulitloxacin synthesis was to decrease 
the steric obstruction of the C-2 substituent toward the C-3 carboxyl group via formation of a 4-
membered ring that connects the N-1 and C-2 atoms. This would possibly improve the binding 
potential of quinolone system to the bacterial enzyme [ 14]. 
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On the same path, Matsuoka et a/., reported the synthesis of 6-tluoro-1-methyl-4-oxo-7-( 1-
piperazinyi)-4H-[ I ,3]thiazeto[3,2-a]quinoline-3-carboxylic acid (NM394). This compound was 
also showing excellent in vitro antibacterial activity [ 15) (Figure 3.3). 
Ito et al. , have reported another compound from this series a 4-oxo-1 ,4-dihydro-[ I ,3] 
thiazeto[3 ,2-a ]quinoline-3-carboxylic acid derivative, as a potent antibacteria l, anticancer, and 
anti-HIV agent [16] (Figure 3.4). 
0 
Figure 3.3. Compound reported by Matsuoka eta/. [ 15] 
0 
F 
Figure 3.4. Compound reported by Ito et a/.[ 16] 
The novel synthetic procedure reported by A. Ahmed el al. , for the synthesis of the 4-oxo-1 ,4-
dihydrobenzo[h][1 ,3]thiazeto[3,2-a]quino line-1 ,3-dicarboxylic acid is shown in Figure 3-5. In 
this procedure, sod ium salt of diethyl malonate was a llowed to react with naphthylisothiocyanate 
and the resulting product was further reacted with ethy l bromoacetate. The open chai n derivative 
obta ined was then cyclised by heating under vacuum at 180-185 °C to afford the corresponding 
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benzo[h]quinolone carboxylic acid ester. This scaffold was subjected to several oxidative 
cyclization reactions to obtain the targeted thiazeto[3,2-a]quinoline derivatives [2c,3]. 
MeCN/ lhr/rt # ~ COOEt 
NaH/Diethylmalonat.... I  & ~ g-Ni NCS I N "<: BrCH2COOEtffHF )lloo I hr/rt # ~ COOEt 
OH 
COOEt 
cY ls 175- l&o·c 7~C00Et 10-15 min H COOEt 
OH 0 
NaOH/EtO ... 
Ioo•c J4hr 
COOEt 
Kl/K2C03/Dibromopropane 
S 70°C/ DMF 
lCOOEt 
Figure 3.5. Synthesis of 4-oxo-thiazeto [3, 2-a]quinoline nucleus. 
In continuation of our current research on thiazeto [3 , 2-a]quinolones and in order to expand our 
knowledge on the chemistry and biological profiles of th is nuc leus, we attempted the synthesis 
and biological evaluation of modified th iazeto[3,2-a]quinolone analogues of compounds reported 
by Ahmed et. AI. [2a]. 
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3.2 Materials and Methods 
Our approach to the synthesis of the target compounds starts with 3-tluorophenylisothiocyanate 
or simply phenylisothiocynate. In the first step, sodium hydride is reacted with diethylmalonate 
in acetonitri le to afford sodium salt of diethyl malonate. To this a solution of 
phenylisothiocyanate or 3-tluorophenylisothiocyanate is added drop-wise and the mixture is 
stirred at room temperature for 4 hour to yield the salts la-b. These salts are further reacted with 
ethylbromoacetate in anhydrous THF under ice coo ling to obtain compound 2a-b as shown in 
Scheme 3.1 a. 
~ __ N_.w_o_i•th..:..;~-:-:-""_e~M_eCN_--I~AMNI 1:," ,cooEt A~NCS , I 
H COOEt 
la,A=H; lb,A = F 
BrCH2C02Et/THF 10 . 12 hrtrt 
~ S~COOEt 
A~~~COOEt 
H COOEt 
2a, A= H; 2b, A= F 
Scheme 3.1a 
Compounds 2a-b, which are open-chain unstable intermediates, are immediately subjected to 
thermal cyc lization by heating for I 0-15 mtn under vacuum at 180- 190 °C to afford 
Compounds3a-b, as shown in Scheme 3.1 b. 
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EtOOC 
ri'l ) 
~~JyCOOEt 
COOEt 
2a, A= H; 2b, A= F 
10-lSMin 
Scheme: 3.1b 
OH 
COOEt 
3a, A = H; 3 b, A = F 
s 
l_COOEt 
Following the oxidative cyclization procedures reported by Ahmed, A. eta!. [2b] with minor 
modifications, compounds 3a-b are later reacted with I ,2-dibromopropane in the presence of KI 
and K2C0 3 to obtain compounds 4a and 4b, as depicted in Scheme 3.2. 
OH 
O COOEt KI/ K2C03/ 1,2-dibromopropane h DMFI 70 °C/ 24 Hours A N S 
0 
~COOEt 
V~.Jl A NYS 
l._COOEt COOEt 
3a, A= H; 3b, A= F 4a, A = H; 4b, A = F 
Scheme 3.2. Formation of compounds 4a-b 
According to a ll previously reported procedures this cyclization reaction can only be possible in 
presence of vicinal d ihaloa lkane and but not in presence germina l analogues. [9-13). It is 
interesting to know that no part of the vicinal dihaloalkane participates in the fi nal structure of 
the thiazetoquinolne structura l features. This phenomenon suggests the catalytic role of the 
vicinal dihaloalkane in thi s oxidative cyclization procedure, rather than a contributor to the 
structural feature of the target compounds. [2c] 
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Based on our previously reported mechanism of formation of vicinal dihaloalkane catalyzed 
thiazeto-quinolines [2c], a likely pathway for formation of our tricyclic derivatives is suggested 
as following. Namely, the 4-oxo-thiazetoquinoline nucleus is fo rmed via reaction of the 
carbanion of the ethoxycarbonylmethylsulfide group at the C-2 position of the quinoline ring 
with a pseudo halogen (IBr), formed via reaction of iodide anion with the vicinal dihaloalkane, 
or a halogen (h), followed by nucleophilic attack of the N-1 on the halogenated carbon and the 
departure of halogen. The role of the vicinal dihaloalkane in this process is the provision of a 
pseudo halogen such a IBr without direct interaction with quinoline system as depicted in the 
following scheme [2c]. 
Mechnism 3.1 Proposed Mechanism for scheme 3.2 
In order to reassure this mechanism and participation of the pseudohalide (iodobromide), formed 
via the reaction of I ,2-dibromopropane and Kl, in the oxidative cyclization of Compound 3 to 
Compound 4, we attempted the reaction of 3a with iodobromide or iodine in presence of K2C03. 
In both attempts we were able to obtain Compound 4 in reasonable yields. 
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Compounds 4a-b were further saponified by heating in alkaline alcoholic solution at I 00°C for 4 
hours, as shown in Scheme 3.3. 
Compound Sb was further gone under nucleophil ic substitution reaction with several ammes 
using the procedures reported by Tabart, M. et al. [17], Antoine, M. et al. [18], and Massari , S. 
et al. [ 19] with some alterations to obtain the corresponding C-7 substituted derivatives 6a-h as 
depicted in Scheme 3.4. 
0 
ciCOOEt I 
A NYS 
NaOH/EtOH 
4 Hr/ JciQ:; 
COOEt 
4a, A = H; 4b, A = F Sa, A = H; 4b, A = F 
Scheme 3.3. Formation of compounds Sa-b 
0 0 
~~ ~ 
1 
COOH _su_b_sti_tu_te_d_am_i_ne_s_ ~~ COOH 
~~•)-_ DMF/ I00-130°C ~•)-_ 
F NYS X NYS 
Sb 
COOH 
COOH 
6a-e 
Scheme 3.4. Synthesis of compounds 6a-h 
6a; X= Piperazine, 30% 
6b; X= methylpiperazine 27% 
6c; X= Pyrrolidine 17% 
6d ; X= Morpholine 2 1% 
6e; X= Pyrrol 37% 
3.3 In vitro microbiological testing 
In order to evaluate the biological activities of newly synthesized compounds Sa-b and 6a-c, 
antimicrobial screening was carried out, using broth dilution method to determ ine their M ICs. 
The 96-well microtiter plate-based serial dilution method was adopted [20]. In accordance with 
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the protocols followed by Tahlan bacteriology Laboratory at the Dept. of Biology, Memorial 
University, nalidixic acid and ampicillin were used as controls. E. coli, B. subtilis, S. 
epidermidis, P. jluorescens, and M luteus were used as the test organisms. Stock solution of 
concentration I 0000 f.1M was prepared by appropriate weight of test compounds. I 00 fll of sterile 
media was added to the wells I A-1 H (Figure 3.6). To the wells 2A-2H to II A-ll H, 50 fll of 
sterile media was added. To each well I A-1 H, 2 fll of the stock solution of test compound was 
added and mixed properly. Using a multichannel pipette, 50 fll of the media from wells I A-1 H 
was transferred to the wells 2A-2H and mixed properly. This procedure was repeated till the 
wells II A-ll H. To the wells 12A-12H, only 50 fll of the sterile media was added without any 
test compound. To each well, 50 fll of various microbial suspensions was then added. This 
resulted in the effective concentrations of 100, 50, 25, 12.5, 36.25, 3.125, 1.5625, 0.78125, 
0.390625 and 0.1953125 f.1M in the wells 1-11 , respectively. Wells were then allowed to 
incubate at the respective temperatures. Plates containing M luteus and B. subtilis were 
incubated at 30°C for 48 hours. Plates containing S.epidermidis, P. jluorescens, and E. coli were 
incubated at 37°C for 48 hours. Nalidixic acid and ampicillin were used as the reference 
standards. After incubation, plates were observed visually to detect the presence of bacterial 
growth. 
Figure 3.6. A 96 well plate 
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3.4 Molecular Docking 
3.4.1 Methods 
Docking calculations were carried out according to the Docking Server methodology [21 ]. The 
MMFF94 force field [22] was used for energy minimization of ligand molecule using Docking 
Server. PM6 semi empirical charges calculated by MOPAC2009 (J. P. Stewart, Computer code 
MOPAC2009, Stewart Computational Chemistry, 2009) were added to the ligand atoms. Non-
polar hydrogen atoms were merged, and rotatable bonds were defined. 
Docking calculations were carried out on human topoisomerase II and IV structures with the pdb 
codes 4FGH, ISI6 and 3FOE. Essential hydrogen atoms, Kollman united atom type charges, and 
solvation parameters were added with the aid of AutoDock tools [23]. Affinity (grid) maps of 
25 x25 x25 A grid points and 0.375 A spacing were generated using the Autogrid program [23]. 
AutoDock parameter set- and distance-dependent dielectric functions were used in the 
calculation of the vander Waals and the electrostatic terms, respectively. 
Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the 
Solis & Wets local search method [23]. Initial position, orientation, and torsions of the ligand 
molecules were set random ly. Each docking experiment was derived from I 00 different runs that 
were set to terminate after a maximum of 2500000 energy evaluations. The population size was 
set to 150. During the search, a translational step of 0.2 A, and quaternion and torsion steps of 5 
were appl ied. 
3.4.2 Background 
Topoisomerases are A TPases belonging to the GHKL (Gyrase, Hsp90, histidine Kinase, mutL) 
fami ly. Their mechanism of function is to cut both strands of the DNA helix using the energy 
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derived from ATP hydrolysis. As a consequence, there are more ways to inhibit the enzyme's 
action, such as inhibiting A TP binding or blocking DNA cleveage. Thus, molecular docking 
studies on topoisomerase inhibition are focused on the A TP binding site and on a possible ligand 
binding site at the DNA-protein interface. 
Quinolones are known to inhibit type IIA topoisomerases, the topoisomerase II (bacterial DNA 
gyrase) and the bacterial topoisomerase IV. Therefore, the goal of this study was to evaluate the 
inhibition potential of these compounds on topoisomerase II and IV. 
There are a number of topoisomerase structures available in Protein Data Bank; however, 
architecture of the full-length enzyme has remained undefined until recently. In 2012, Schmidt, 
B.H. et al. , has published the first full length structure of topoisomerase II of Saccharomyces 
cerevisiae S288c (PDB code 4GFH) complexed with DNA and a non-hydrolysable ATP analog 
enabling molecular docking studies on an enzyme in a biologically relevant conformation. 
Although this structure (4GFH) does not contain bound ligand at the DNA-protein interface, 
alignment with topoisomerase II structure (3QX3) with a bound ligand has revealed the potentia l 
binding site of an inhibitor exerting its effect at the DNA binding site of the prote in, as shown in 
Figure 3.7 [24]. 
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Figure 3.7. A TP and DNA binding s ites in PDB accession code 4GFH.(Ligands are indicated 
w ith spheres)[24] 
In contrast to topoisomerase II, no fu ll length structure of bacterial topoisomerase IV exists in 
Protein Data Bank. Thus, DNA bound and A TP bound structures of bacterial topoisomerase IV 
were selected separately. PDB entry 1S16 was used for the ATP binding site, whereas PDB entry 
3FOE was used for docking at the DNA-protein interface. 
3.4.3 Results 
The resulting docking energies are shown on Table I. All compounds had more favorable 
binding on the DNA binding site as compared to the A TP binding site. It can be seen that 
binding of larger derivates is more favorab le at the DNA binding site; while the smaller ATP 
binding site accommodates smaller ligands due to possible steric reasons. 
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Table 3.1. Lowest docking energies of the investigated compounds at topoisomerase II and JV 
binding sites. (Most favorable energies are indicated with bold letters) 
4GFH ATP 4GFH DNA 1S16 ATP 3FOE DNA 
Ligand/Protein 
binding site binding site binding site binding site 
6a -8.2 kcal/mol -13.2 kcal/mol -4.5 kcal/mol -8.6 kcal/mol 
6c -8.2 kcal/mol -11.4 kcal/mol -6.2 kcal/mol -8.4 kcallmol 
6b -8.6 kcal/mol -13.0 kcal/mol -5.8 kcal/mol -8.2 kcal/mol 
Sb -7.9 kcal/mol -I 1.6 kcallmol -7.0 kcallmol -7.0 kcal/mol 
Sa -7.6 kcal/mol - 11.5 kcallmol -7.2 kcallmol -7.2 kcal/mol 
Figure 3.8 shows the interactions of Compound 6a with the ATP binding site of 4GFH. A strong 
coulomb interaction can be observed between the terminal amino group of L YS 14 7 and 
carboxylate group of the ligand. This carboxylate accepts a hydrogen bond from ASN70 at the 
same time. lLE 120, PHE 121 and JLE I 04 form hydrophobic interactions with the aromatic rings 
ofthe ligand. 
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Figure 3.8 Lowest energy docking result of compound 1 at the 4GFH A TP binding site 
Figure 3-9 shows the interaction of compound 6a at the DNA binding site of 4FGH. As can be 
seen, DNA bases form strong hydrogen bonding interactions with the ligand forming a very 
stable complex. This complex is further stabilized with a coulomb interaction fo rmed with 
ARG475. 
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Figure 3.9. Lowest energy docking result of compound 1 at the 4GFH DNA binding site 
Figure 3. 10 shows the highest energy binding of compound 6a at 1 S 16 ATP binding site. The 
high docking energy indicates that the binding site of 1 S 16 is not able to accommodate 
compound 6a due to steric hindrance. Therefore, compound 6a can on ly bind in a nonfavourable 
conformation. The intermolecular interactions are favorab ly stabi lizing the complex. 
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Figure 3.10. Lowest energy docking result at the IS 16 A TP binding site 
Figure 3-11 shows the binding of compound 6a at the 3FO E DNA binding site. The interactions 
are very similar to that of observed at the DNA binding site of 4GFH. Namely, strong hydrogen 
bonding interactions are observed with DNA bases, and ARG456 also contributes to complex 
stabilization by forming a strong coulomb interaction with the carboxylate group of the ligand. 
As there are fewer bases forming interactions with the ligand, higher docking energy is 
calculated as compared to 4GFH binding at the DNA binding site. 
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Figure 3.11. Lowest energy docking result at the 3FOE DNA binding site 
3.4.4 Summary 
Interactions of thiazetoquinolone derivates were investigated with topoisomerase II and IV 
proteins using molecular docking methods. Analyzing the available X-Ray structures with bound 
ligand, two potential binding sites were defined; namely, the ATP binding site and a site at the 
protein-DNA interface in a DNA bound conformation. The ligands were docked into both 
binding sites of topoisomerase II and IV. Our results indicate that the DNA binding sites are 
more favorable for binding the investigated compounds. Moreover, it was shown that binding of 
larger derivates is more favorable at the DNA binding site; while the smaller A TP binding site 
accommodates smaller ligands due to steric reasons. 
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3.5 Results and discussions 
3.5.1 Antimicrobial assay results 
Compounds were tested against E. coli, B. subtilis, S. epidermidis, P. jluorescens, M luteus 
using nalidixic acid and ampicillin as standard. Biological Assay results against Testes 
microorganisms are recorded in Table 3.2. 
Table 3.2. Microbiological assay results for tested compounds 
Compound MIC(J.LM) 
M.luteus E. coli S. epidermidis B. subtilis P. fluorescens 
6a > 100 > 100 > 100 > 100 > 100 
6b > 100 > 100 > 100 > 100 > 100 
6c > 100 > 100 > 100 > 100 > 100 
Sa > 100 > 100 > 100 > 100 > 100 
5b > 100 > 100 > 100 > 100 > 100 
Nalid1xic ac1d > 100 1.6 > 100 > 100 > 100 
Ampicillm > 125 >62.5 >62.5 > 125 >62.5 
3.6 Conclusion 
The quinolone-based system is an excellent scaffold for design of various c lasses of bioactive 
molecules. Its several distinctive structural features have led researchers to design and synthesize 
different kinds of molecules. In this study, a series of novel Cr substitutedthiazeto[3 ,2-
a]quino lones derivative were synthesized and tested for their antibacterial activity against E. coli, 
B. subtilis, S. epidermidis, P. fluorescens, and M luteus. The test results revealed the lack of 
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antimicrobial activity of these compounds. In order to explore the cause behind the lack of 
activity, docking experiments were carried out against DNA gyrase and topoisomerase IV. Based 
on our docking results, we concluded that in this type of polycycl ic quinolone systems, deletion 
of fluorine can consequently eliminate the antimicrobial activity. This can be due to formation of 
a reversible and weak complex with the ATP binding region of the DNA gyrase as well as with 
DNA-GyrA complex. Further structural optimisation and bioassays of these compounds to find 
additional poss ible bioactivities are ongoing in the Daneshtalab group. 
3.7 Experimental 
Solvents and reagents were obtained from commercial suppliers and were used without further 
purification. Melting points are not corrected. 1 H NM R spectra were recorded on a Bruker 
A VANCE-500 MHz NMR spectrometer and on Bruker AVANCE-300 MHz NM R spectrometer 
using tetramethylsilane as an internal standard. Mass spectra were obtained on an Agilent II 00 
series LC/MSD chromatographic system. High-resolution mass spectra (El or ES I) were 
obtained on Waters GCT Premier Micromass Spectrometer. Silicycle Ultrapure silica gel (0-20 
f.lm) G and F-254 were used for thin-layer chromatography (TLC), and Silicycle si lia-P 
Ultrapure Flash si lica gel (40-63 f.tm) was used for flash co lumn chromatography. TLC was 
conducted on Polygram SIL G/UV254 precoated plastic sheets. The reaction yields are included 
in corresponding schemes. 
Sodium 3-ethoxy-2-(ethoxycarbonyl)-3-oxo-1-(phenylamino)prop-1-ene-1-thiolate (la) 
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To a suspens1on of sodium hydride (0.6 g, 25 mmol) in acetonitrile (50 mL) at 5-l 0 °C, 
diethylmalonate (4 mL, 26.34 mmol) was added gradually with constant stirring over a period of 
15 min. This mixture was then stirred at 5-l 0 °C for additional 30 min, then brought to room 
temperature, allowed to stir for another 30-40 min. Phenyl isothiocyanate ( 19.41 g, 143.6 mmol) 
was added to the reaction mixture portion wise over a period of 30 minutes at the same 
temperature and the mixture was stirred overnight. After around 24 hours of stirring, evaporation 
ofMeCN yielded a yellowish a yel low solid which was washed with Et20. 1H NMR (300 MHz, 
Chloroform-d) o 7.10 - 6.96 (m, 2H), 6.76 - 6.58 (m, 3H), 4.19 (q, J = 8.0 Hz, 4H), 3.60 (s, I H), 
1.26 (t, J= 16.0 Hz, 6H). APCI-MS: 318.068 (M+ + 1,100). 
Sodium 3-ethoxy-2-( ethoxycarbonyl)-1-[ (3-fluorophenyl)amino]-3-oxoprop-1-ene-1-thiolate 
(1b) 
This compound was prepared according to the same procedure as that applied for 1a us ing 3-
fluorophenylisothiocyanate (22 g, 143.6 mmol) instead of phenyl isothiocyanate; yellow 
crystals; 1 H NMR (300 MHz, Chloroform-d) 8 7.10 (td, J = 7.5, 5.7 Hz, I H), 6.79 (dt, J = 8.9, 
2.0 Hz, I H), 6.65- 6.51 (m, I H), 6.41 (dt, J = 7.5 , 2.0 Hz, I H), 4.19 (q, J = 8.0 Hz, 4H), 3.60 (s, 
I H), 1.26 (t, J = 16.0 Hz, 6H). APCI-MS: 335 .30 (M+ + 1,100). 
Ethyl 2-[(ethoxycarbonylmethyl)sulfanylylj-4-hydroxyquinoline-3-carboxylate (3a) 
To the above ye llow solid 1a ( 1.75 g, 5.44 mmol) in THF (50 mL) was added BrCH2C02Et (0.6 
mL, 5.44 mmol) dropwise at 0 °C and the mixture was stirred fo r I 0-1 2 hour at room 
temperature. The so lvent was then evaporated, extracted with CHCb and dried over Na2S04• 
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The organic layer was evaporated by rotary evaporator to give yellow oil (2). The obtained oil 
was heated at 180-190 °C in an oi l bath under vacuum for I 0-15 min. The resulting oil was 
solidified, then washed with ether to afford compound 3a as dark yellow amorphous solid. Mp 
145-150 °C, 1H NMR (300 MHz, Chloroform-d) 8 7.88 (dd, J = 7.4, 1.5 Hz, 1 H), 7.79- 7.61 
(m, 2H), 7.43 (td, J = 7.4, 1.6 Hz, I H), 4 .35-4.12 (m, 6H), 1.27 (dt, J = 21 .1 , 5.9 Hz, 6H). HR-
MS (TOFEI) calcd for C1 6H 11NOsS: (335 .374); Found (335.330), Calculated LogP: 4.78 +/-
0.69. 
E thy I 2-[ ( ethoxyca rbonylmethyl)sulfanylyl] -7 -fluoro-4-hyd roxyq uinoline-3-carboxylate 
(3b) 
This compound was prepared according to the same procedure as that applied for 3a using lb 
( 1.85 g, 5.44 mmol) instead of la ; brick red crystals; Mp 148-152 °C. 1 H NM R (300 MHz, 
Chloroform-d) 8 7.97 (dd, J = 7.5, 5.0 Hz, I H), 7.46 (dd, J = 8.0, 1.6 Hz, I H), 7.16 (td, J = 7.7, 
1.4 Hz, I H), 4.35- 4. I 2 (m, 6H), 1.27 (dt, J = 2 I. I, 5.9 Hz, 6H). HR-MS (TOFEI) calcd for 
C16H16NOsSF: (353.364); Found (353.30 1). Calculated LogP: 4.95+/- 0.72 
Diethyl 4-oxo-4H-[1,3] thiazeto[3,2-a]q uinoline-1 ,3-dicarboxylate ( 4a) 
1) Oxidative Cyclization with KI and 1,2-dibromopropane 
To a mixture of 3a (0.335 g, I mmol) and K2C03 (0.386 g, 2.8 mmol) in anhydrous DMF (25 
mL) under nitrogen atmosphere was added I ,2-dibromopropane (0.56 g, 2.8 mmol) a long with 
Kl (0.464 g, 2.8 mmol). The reaction mixture was heated at 70 °C for 24 h, then brought it at 
room temperature and with help of cone HCI acidify it t ill pH 1-2 and then poured into ice-
97 
H20. The resulting thiazetoquinoline derivative was collected by filtration and recrystrallized 
with hexane: CHCI3 (I :4) to afford brick red crystals; yield 68%. 
2) Oxidative cyclization with iodobromide and/or iodine 
To a mixture of 3a (0.335 g, I mmol) and K2C03 (0.386 g, 2.8 mmol) in anhydrous DMF (25 
mL) under nitrogen atmosphere was added idobromide and /or iodine (2.8 mmol). The reaction 
mixture in case of iodobromide was stirred at room temperature for 24 h (in case of Iodine the 
reaction mixture was heated at 70 °C), then brought it at room temperature and with help of 
cone. HCI acidify it till pH 1-2 and then poured into ice-H20. The resulting thiazetoquinoline 
derivative was collected by filtration and recrystallized from hexane: CHCb (I :4) to afford 
Brick red crystals. Yield: 44 %, Mp 225-229 °C. 1H NMR (300 MHz, Chloroform-d) 8 8.14 
(dd, J = 7.5 , 2.0 Hz, I H), 7.65 (td, J= 7.5 , 2.0 Hz, I H), 7.10 (dd, J= 7.5, 2.0 Hz, I H), 6.90 (td, 
J = 7.4, 2.0 Hz, I H), 5.73 (s, I H), 4.21 (dq, J = 14.3, 5.9 Hz, 4H), 1.24 (dt, J = 9.0, 5.9 Hz, 6H). 
HR-MS (TOFEI) calcd for C1 6H 1sNOsS: (333.358); Found (333.315), Calculated LogP: 4.38+/ -
1.1 0. 
Diethyl 7 -fluoro-4-oxo-4H-[1 ,3 ]thiazeto [3,2-a Jq uinoline-1,3-d icarboxy late( 4b) 
1) Oxidative Cyc/ization with KI and 1,2-dibromopropane 
This compound was prepared according to the same procedure as that applied for 4a using 3b 
instead of 3a. 
2) Oxidative cyc/ization with iodobromide and/or iodine 
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This compound was prepared according to the same procedure as that applied for 4a using 3b 
instead of 3a. Mp 223-228 °C. 1 H NMR (300 MHz, Chloroform-d) 8 8.09- 7.98 (m, I H), 6.92 
- 6.79 (m, 2H), 5.73 (s, I H), 4.22 (dq, J = 17. 1, 5.9 Hz, 4H), 1.24 (dt, J = 9.0, 5.9 Hz, 6H). HR-
MS (TO FE I) calcd for C 16H 14 0 5SF: (351.348); Found (351.302) ), Calculated LogP: 4 .56+/-
1.14. 
4-0xo-4H-[1,3]thiazeto[3,2-a]quinoline-1,3-dicarboxylic acid (Sa) As the procedure 
reported, we have stirred and heated the mixture of ester 4a ( .333 g, I mmol) and sodium 
hydroxide in water (20 mL) at I 00 °C for 3-4 h. After cooling, the reaction mixture was 
neutralized with hydrochloric acid (I M), extracted with CH2Cb_ dried over MgS04, then the 
so lvent was evaporated. The solid obtained was purified by recrystallization from EtOH to 
afford compound Sa as red amorphous powder. Mp 220-225 °C. 1H NMR (300 MHz, 
C hloroform-d) 8 9.67 (s, 2H), 8. 15 (dd, J = 7.5. 2.0 Hz, I H), 7.65 (td, J = 7.5, 2.0 Hz, I H), 7.09 
(dd, J = 7.5, 2.0 Hz. I H), 6.90 (td, J = 7.4, 2.0 Hz, I H), 5.77 (s, I H). HR-MS (TOFEI) calcd for 
C 12H7N05S: (277.250); Found (277.004). Calculated Log P: 2.34+/- 1.1 0. 
7-Fluoro-4-oxo-4H-[1,3Jthiazeto[3,2-aJquinoline-1,3-dicarboxylic acid(Sb) This compound 
was prepared according to the same procedure as that applied for Sa us ing 4b instead of 4a. 
Brick red solid was extracted. Mp 226-230 °C. 1H MR (300 MHz, Chloroform-d) 8 9.67 (s, 
2H), 8. 10 - 7.98 (m, I H), 6.93 - 6.80 (m, 2H), 5.78 (s, I H). HR-MS (TOFEI) calcd for 
C 12H6N05SF: (295.240); Found (294.990), Calculated LogP: 2.52+/- 1.1 4. 
4-0xo-4 H-7 -(piperazin-l-yl)[l,3]thiazeto[3,2-a]quinoline-1,3-dicarboxylic acid (6a) 
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To a mixture of compound 5b (0.79 g, 2.00 mmol) in DMF ( 10 mL), 0.86 g (10 mmol) of 
piperazine was added and the mixture was stirred at II 0 °C for 15-18 h. It was then brought to 
room temperature. The title compound was precipitated by the addition of I 00 ml saturated 
solution of sodium chloride. The precipitate was washed with water and purified by 
recrystallization from EtOH; ye llow solid; Mp 154-159 °C. 1 H NMR (300 MHz, Chloroform-d) 
o 9.67 (s, 2H), 7.83 (d, J = 7.5 Hz, I H), 6.57 (dd, J = 7.4, 2.0 Hz, I H), 6.37 (d, J = 2.0 Hz, I H), 
5.71 (s, I H), 3.50 (t, J = 5.0 Hz, 2 H), 3.22 (t, J = 5.1 Hz, 2H), 2.89 (t, J = 5.1 Hz, 4H), 1.18 (s, 
I H). HR-MS (TOFEI) calcd for C 16H 14N05SF: (361.231); Found (361.302), Calculated LogP: 
1.23+/- 1.45. 
7 -( 4-Methylpiperazin-1-yl)-4-oxo-48-[1 ,3] thiazeto [3,2-a ]q uinoline-1 ,3-d icarboxylic acid 
(6b) 
T his compound was prepared utilising the procedure employed for the preparation of compound 
6a, us ing (0.59 g, 2.00 mmol) of compound 5b and 1.0 g (I 0 mmol) of methyl piperaz ine; Black 
powder; Mp 130-1 35 °C. 1H NM R (300 MHz, Chloroform-d) o 9.67 (s, 2H), 7.83 (d, J = 7.5 
Hz, I H), 6.58 (dd, J = 7.4, 2.0 Hz, I H), 6.42 (d, J = 1.9 Hz, I H), 5.77 (s, I H), 3.54 (t, J = 5.1 
Hz, 2H), 3.35 (dd, J = 5.4, 4 .8 Hz, 2H), 3.20 (t, J = 5.1 Hz, 4H). HR-MS (TOFEI) calcd for 
C1 7H17NJOsS: (375.242); Found (375.302), Calculated LogP: 1.93+/- 1.44. 
7-(Morpholin-4-yl)-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-1,3-dicarboxylic acid (6c) 
Prepared according to the procedure employed for the preparation of compound 7a, using (0.59 
g, 2.00 mmol) of compound 5b and morpholine (0.87 g, I 0 mmol); dark ye llow precipitates; 
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Mp 136-140 °C. 1 H NMR (300 MHz, Chloroform-d) 8 9.67 (s, 2H), 7.85 (d, J = 7.5 Hz, I H), 
6.56 (dd, J = 7.5, 2.0 Hz, I H), 6.35 (d, J = 2.1 Hz, I H), 5.76 (s, I H), 3.73 (t, J = 4.5 Hz, 4H), 
3.37 (t, J = 4.5 Hz, 4H). HR-MS (TOFEI) calcd for C1 6H14N20 6S: (362.238); Found (362.302), 
Calculated LogP: 1.48+/- 1.44. 
4-0xo-4H-7 -(pyrrolidin-1-yl)-[1 ,3]thiazeto[3,2-a]quinoline-1 ,3-dicarboxylic acid (6d) 
Prepared utilising the procedure employed fo r the preparation of compound Sb, using (0.59 g, 
2.00 mmol) of compound Sb and pyrro lidine (0.71 g, I 0 mmol); yellow powder; Mp 136- 140 
°C. 1H NMR (300 MHz, Chloroform-d) 8 9.67 (s, 2H), 7.80 (d, J = 7.5 Hz, I H), 6.43 (dd, J = 
7.6, 2.0 Hz, I H), 6.25 (d, J = 2.0 Hz, I H), 5.77 (s, I H), 3.49 - 3.33 (m, 4H), 2.46 - 2.28 (m, 
4H). HR-MS (TOFEI) calcd fo r C 16H 14N20 sS: (348 .23 1 ); Found (348.860), Calculated LogP: 
2.54+/- 1.44. 
4-0xo-4H-7 -(1H-pyrrol-1 -yl)-[1 ,3]thiazeto[3,2-a]quinoline-1 ,3-dicarboxylic acid (6e) 
To a mixture of compound Sb (0.59 g, 2.00 mmol) in DMF ( I 0 mL), pyrrol (0.68 g, I 0 mmol) 
was added and the mixture was stirred at II 0 °C for 15- 18 h. It was then cooled down to room 
temperature and the ti t le compound was precipitated by the addit ion of I 00 ml saturated 
solution of sodium chloride. The prec ipitate was washed with water and purified by 
recrystallization from EtOH. Yellow powder, Mp 145- 150 °C. 1H NM R (300 MHz, 
Chloroform-d) 8 9.67 (s, 2H), 8.1 4 (d, J = 7.5 Hz, I H), 7.79 (d, J = 2.0 Hz, I H), 7.70 (dd, J = 
7.5, 2.0 Hz, I H), 7.43 (dd, J = 5.6, 3.4 Hz, 2H), 6.35 (dd, J = 5.6, 3.5 Hz, 2H), 5.78 (s, I H). HR-
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MS (TOFEI) calcd for C16H10N20sS: (342.231); Found (341.892), Calculated LogP: 3.20+/-
1.44. 
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Chapter-4 
Conclusion and Future 
research 
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4.1 Conclusion and future research 
Antibacterial drugs are those which kill or prevent the growth of various strains of 
bacteria. Chemical compounds which have quinolones in their basic ring skeleton cover 
a large part of whole antibacterial group. Nalidixic acid the aborigine of quinolone 
antibacterial class and other very first discovered members of this group were eventually 
fazed out of therapeutic system, either because of development of bacterial resistance or 
their toxic side effects. As discussed in chapter 2 of this thesis, the emerging bacterial 
resistance against quinolone antibacterials is the biggest challenge for researchers. Few 
recent studies on the synthesis and structure-activity relationships of quinolone 
antibacterials have shown that non-fluorinated analogues display additional antibacterial 
activity against resistant antibacterial species [ 1-5]. 
Daneshtalab group has long been involved in quinolone-based research. Numerous 
quinolone based compounds have been synthesized and reported by our group. A 
research done by our previous group member Abeer Ahmed has reported the synthesis of 
a nove14-oxo-benzo[h]thiazetoquinoline derivative [6, 7]. 
As detailed in previous chapters of this thesis, while she was attemting the synthesis and 
biological evaluation of polycyclic quinolones using conventional synthetic procedures, 
she unexpectedly discovered a novel polycyclic 4-oxo-benzo[h]thiazetoquinoline 
derivative. Unfortunately the biological data of this compound were not encouraging. In 
continuation of her research and to generate more data for structure-activity relationships 
of thiazetoquinolone derivatives, we further studied other structural analogues of 
compound shown in Figure 4.1. 
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Where, A is piperazine/methyl piperazine/Morpholine etc. 
Figure 4.1. Structure of synthesized compounds 
In this project we have synthesized a senes of non-fluorinated derivatives of 
thiazetoquinolones using the same synthetic procedure as that of Abeer Ahmed w ith 
minor modifications. In fact, there are numerous studies avai lable on the synthesis and 
bioactivity of angular 4-oxo-thiazolo[3, 2-a ]quino line-3-carboxylic ac ids and other 
su lfur containing polycyclic quinolone derivatives, while there are very few studies on 
the synthesis of 4-oxo-thiazeto [3,2-a]quino lines. In the synthesis described in this 
theses, the 4-oxo-thiazetoquinoline nucleus was formed by the reaction of the carbanion 
at the a lky l sulfide group at the C-2 position of the quinoline ring with the 
pseudohalogen ( IBr), formed when iod ide ion reacted with the vic-dihaloalkane, or a 
ha logen (b) followed by the nucleophilic attack of the N-1 on ha logenated carbon 
followed departure of halogen. The role of vic-dihaloalkane in this reaction is to 
generate the pseudohalogen without direct involvement in the quinol ine nucleus. 
Following a series of five reactions, we were able to collect various 4-oxo-
thiazetoquinoline-3-carboxylic ac id derivatives, in reasonable yie lds. After completing 
synthesis of considerable number of novel compounds, we proceeded for evaluation of 
their biolog ical activity agai nst different bacterial strains. Unlucki ly, none of the 
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synthesized compounds have shown any encouraging results in biological activity. To 
justify the reason behind the loss of antibacterial activity in this series o f compounds, we 
attempted molecular docking on DNA gyrase enzyme. This is a bacterial enzyme which 
is inhibited by quinolones, in order to show their antimicrobial activity. The findings of 
docking studies were quiet interesting. Our synthesized compounds were able to interact 
w ith the ATP binding domain of DNA gyrase as we ll as the DNA-DNA gyrase complex. 
Based on docking energies, it was found that, although the test compounds were 
interacting with the enzyme, they were fo rming a reversible binding with various 
domains of the gyrase enzyme. In general , it has been reported that the cl inically used 
quinolo ne antibacterials form a irreversible binding with the A TP binding s ite of the 
gyrase molecule. The reversible interaction of the test compounds w ith the A TP binding 
site of the gyrase may be the main reason for the low activity of these compounds. 
Quinolones must possess two distinct features in order to act on DNA topoisomerases. 
First feature comes with the ir ability to che late the Mg2+ at the active site and second to 
complex with the A TP binding region. Compo unds synthesized by Dr. A beer Ahmed 
were able to bind w ith the A TP binding region but were not able to make appropriate 
chelation with the Mg+2. This was the cause behind the absence of cytotoxicity [8a-b]. 
This may a lso be the reason for insignificant activity of our compounds. 
As a part of my future research p lan, I wi ll try to work on further structural optimisation 
of my test compounds, to explore various other biological activ ities. One of them will 
include development of some structural analogue of my compound which inc ludes the 
substitution of carboxylic acid group w ith COOC2H5 or CON H2 (Figure 4.2). These 
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substituents will definitely help to chelate the Mg+2 at the active site oftopoisomerase, to 
a larger extent, as compared with the compound which I already synthesized (Figure 
4.1). 
0 
F 
A 
Where, A is piperazine/methyl piperazine/Morpholine etc. 
R1 and R2 are COOH/ COOC2Hs/CONH2 
Figure 4.2: Structure of proposed compound for future research 
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